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ABSTRACT OF DISSERTATION

ASSEMBLY AND DEGRADATION OF A TRIMERIC MEMBRANE PROTEIN ACRB

Multidrug efflux pumps are membrane proteins that actively transport foreign objects out of cells.
The active efflux of these pumps is a critical self-defense mechanism that enables the survival of
bacteria under hostile environments. Efflux pump AcrB is a member of the ResistanceNodulation-Division (RND) super family. In E. coli, it associates with periplasmic protein AcrA
and outer membrane channel TolC to extrude a variety of noxious compounds out of cell from
both the cytoplasm and the periplasm. My dissertation research focused on two aspects of this
multidrug efflux pump: the oligomerization process during the biogenesis of AcrB and its
degradation.

Oligomerization is an important aspect of the structure and function for many proteins and has
been the subject of many studies. However, most of such studies focused on soluble proteins.
The oligomerization process of membrane proteins, including AcrB, is rarely explored. In
chapter 2, the co-assembly of AcrB variants co-expressed in the same cell was used as a tool to
investigate the assembly of AcrB trimers during its bio-production. By monitoring the portion of
pure trimers containing only one type of subunit and hybrid trimers containing a mixture of the

two kinds of subunits, it was found that the oligomerization of membrane proteins is not a
random process as the formation of pure trimer is favored.

In chapter 3, the GALLEX system was used to monitor AcrB oligomerization in cells under the
native condition. Previously GALLEX has only been used to monitor the oligomerization of
small transmembrane proteins. By constructing a series of fusion proteins with different linker
length between LexA and AcrB, and optimizing inducer concentration, we finally developed a
system that could be used to differentiate AcrB trimers of different oligomerization affinities.

While chapters 2 and 3 focus on the trimerization of AcrB, a critical step of its biogenesis,
chapters 4 and 5 focus on its life time and degradation. In chapter 4, the life time of AcrB was
measured by incorporating non-natural amino acid azidohomoalanine (AHA) into protein
translation. Using this method, it was determined that that the half-life of both AcrA and AcrB in
E. coli were six days. The surprisingly long lifetime of these detoxification proteins might
represent a strategy by the bacteria to conserve energy and maximize their competition niche for
survival in a hostile environment.

In chapter 5, the degradation process of ssra tagged AcrB was investigated. In-vivo degradation
test showed that properly inserted AcrB can be digested after addition of ssra-tag to its Cterminus. It was found that cytoplasmic unfoldase-protease complex ClpXP and chaperone SspB
are involved in the degradation. In vitro assay is still being optimized to quantitatively analyze
the activity of ClpXP in the degradation of AcrB.
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Chapter I Introduction

1.1 Protein Oligomerization
1.1.1 Advantages of Protein Oligomerization
Bioinformatics studies have revealed that more than 35% of proteins exist and function as
oligomers instead of monomers.1 Oligomeric proteins have multiple peptide chains which can be
the same (for homo-oligomerization) or different (for hetero-oligomerization).2 Oligomerization
has brought in many advantageous features for organisms in many different aspects. 3 First of all,
oligomeric proteins are more stable than monomer proteins.4 The stability advantage relies on the
fact that oligomeric proteins have reduced surface area, which provides proteins more protection,
and makes them more resistant to degradation and denaturation compared with monomeric
proteins.5-7 Such stability has been exploited by thermophilic organisms. To improve thermostability of protein, an increase in oligomerization state has been observed among proteins from
thermophilic organisms.8 Another example is the hexameric insulin that exists in crystalline
granule and resists protease digestion. As soon as the oligomer dissociates in blood, monomer
insulin is rapidly degraded.9

More significantly, there are many functional advantages for oligomeric proteins. First,
oligomerization provides protein a possibility to adopt a variety of symmetrical structures,
including rings, cages, or funnels, and therefore are suitable for specific morphological functions.
One example is the E. coli Wza protein, an outer membrane protein that is responsible for
transporting lipid-linked polysaccharides across the periplasm and outer membrane (Figure
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1.1).10 Oligomerization of eight monomers leads to the formation of a large tunnel with a central
cavity of 15,000 Ǻ3, which is necessary for exporting polysaccharides across the outer membrane.

Figure 1.1 Crystal structure of Wza protein of E. coli. Each monomer is labeled in different color.
Left image is the view of central cavity from periplasm. Right image is the side view of the
octamer protein. Created from 2J58.pdb.10

Second, the equilibrium between association and dissociation can regulate activity of proteins.1113

In many enzymes, residues from more than one subunit form active sites, which are located on

the interface. Oligomerization stimulates activity, and dissociation results in activity decreases. 14
Glutamine synthetase of bacteria is an enzyme involved in nitrogen metabolism. It catalyzes the
condensation of glutamate and ammonia to form glutamine.15 Bacterial glutamine synthetase is
functional in its dodecamer form, which is superimposed by two face-to-face hexameric rings.
2

Oligomerization brings residues from adjacent monomers together to compose the active site,
which binds adenosine triphosphate (ATP) and glutamate at opposite ends. For each enzyme
there are a total of 12 active sites. Upon dissociation, activity of this enzyme drops.16, 17

Third, oligomeric proteins can provide multiple points of interaction to increase the binding
strength between the ligand and the protein, while monomeric proteins usually have one binding
site. Hia is an autotransporter protein expressed in many Gram-negative pathogenic bacteria such
as Haemophilius influenza, which plays important roles in the pathogenesis of both systemic
diseases such as meningitis and sepsis, and localized respiratory tract diseases including otitis
media and bronchitis.18 it has been confirmed that colonization of these pathogens is promoted
by adhension proteins such as Hia. Hia is a highly stable trimer partially embedded in the outer
membrane and its adhensive activity comes from its binding domains, HiaBD1 and HiaBD2
(Figure 1.2).19 HiaBD1 is composed of three acidic binding pockets, each provided by one
monomer. These binding pockets provide multiple interactions with receptor molecules
simultaneously and thus strengthen the binding of Hia to specific receptor. It was reported in
2006 that the trimeric structure increases the adhesive affinity of Hia for host respiratory
epithelial cells through multivalent binding and leads to infection.19

3

Figure 1.2 Trimeric structure of the HiaBD1. Residues composed of acidic binding pocket in one
monomer are color-labeled in red. This image is created from 1s7m.pdb.

Except for multivalent binding, another important aspect of oligomers cooperativity is allosteric
regulation.20, 21 Allosteric regulation is commonly observed in oligomeric enzymes, in which
binding of a ligand to the non-active site of enzyme, usually in one subunit, changes the
conformation of the protein, and subsequently affects the binding affinity of the ligand to another
subunit in the same oligomer.22 A classic example of allosteric regulation is the Bohr Effect of
the tetrameric hemoglobin, in which the affinity of one subunit for oxygen is decreased when
another subunit binds carbon dioxide. 23

Allosteric regulators can modify activity of enzymes by changing the oligomerization state of
proteins.24,

25

Carbamoyl phosphate synthetase (CPS) in bacteria catalyzes the synthesis of
4

carbamoyl phosphate from glutamine or ammonia and bicarbonate with hydrolysis of ATP.26
The basic building block of this enzyme is a (αβ) monomer. It has two oligomerization states,
one is (αβ)2 dimer, which is inactive. The other is its active form, (αβ)4 tetramer. The
oligomerization state of CPS can be regulated by allosteric ligands, which are metabolites
ornithine, inosine monophosphate (IMP), and uridine monophosphate (UMP). Ornithine and
IMP are activators, since binding of these effectors to the allosteric domain promote transition
from dimer to tetramer. UMP is an inhibitor which stabilizes the dimer of CPS and inhibits
formation of active tetramer.27

5

1.1.2 Experimental Techniques in the Study of Protein Oligomerization
As discussed above, oligomerization is an important aspect in the study of protein structure and
function. Many approaches have been developed to investigate the kinetics and thermodynamics
of protein oligomerization.28-31 However, compared with soluble protein, thermodynamic
analysis of membrane protein has been hampered by various experimental difficulties. 32 Since
membrane proteins reside in lipid bilayer membrane rather than the aqueous cytoplasm, features
of detergent micelles or lipid bilayers must be considered when studying membrane proteins.
Currently, several techniques have been developed to study the oligomerization of membrane
proteins, including sedimentation equilibrium analytical ultracentrifugation, Fӧrster Resonance
Energy Transfer (FRET), disulfide cross-linking, and in vivo systems such as TOXCAT and
GALLEX.

Sedimentation equilibrium analytical ultracentrifugation is one of the most popular techniques
used in the determination of the stoichiometry and stability of membrane protein complexes. 33 It
can be used to determine the oligomerization state of a protein, and measure the association
constant in a monomer-oligomer equilibration.34 In this method, samples are subjected to
ultracentrifugation at a high speed to induce protein sedimentation. During ultracentrifugation, a
protein concentration gradient is formed in the sample. In the meantime, diffusion acts as an
opposite force to disrupt this concentration gradient. Eventually, a balance between
sedimentation and diffusion is achieved and while the sample is still spinning, absorbance is
measured to obtain the concentration distribution in the equilibrium system. Concentration is a
function of position (or radius) within the ultracentrifugation cell. By plotting the absorbance
value at a specific wavelength vs. radius, information like molecular mass and thermodynamic

6

constant can be obtained after mathematical analysis. For membrane protein, the research subject
is always protein-detergent complexes instead of only protein and this problem can be
circumvented by choosing a detergent whose density matches that of the solvent, so that
detergent in the system will not affect test result.

FRET has been exploited for measuring the thermodynamics of transmembrane helix
dimerization.35-37 FRET is a useful tool in studying protein-protein interaction, protein-DNA
interaction, and protein conformational changes.38-40 The basic mechanism is energy transfer
between two chromophores, for which the absorption spectrum of the acceptor must overlap the
fluorescence emission spectrum of the donor (Figure 1.3A). When placed in close proximity
(typically 10-100 Ǻ), energy transfer will take place between donor and acceptor through dipoledipole coupling (Figure 1.3B).41 By linking donor and acceptor chromophores to different biomolecules respectively, and measuring the FRET efficiency, association between target biomolecules can be detected.
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A.

B.
Figure 1.3 Schematic mechanism of FRET. A. In a donor-acceptor pair, the fluorescence
emission spectrum of donor must partly overlap with the absorption spectrum of acceptor. B.
When donor and acceptor are in proximity, energy transfer will occur. In this process,
fluorescence emission of donor decreases while emission of acceptor increases.

In 1994, the Engelman group utilized FRET to study glycophorin A helical transmembrane (GpA
TM) domain dimerization in phospholipid bilayer.42 Two populations of GpA TM peptides were
separately labeled with donor chromophore 2, 6-dansyl chloride or acceptor chromophore dabsyl
chloride. And when association between GpA TM occurs, quenching of 2,6-dansyl chloride by
8

dabsyl chloride was detected. By fitting the detected energy transfer to specific donor-acceptor
ratio, GpA TM was found to form a dimer in lipid bilayer.

Subunit interaction can also be detected by cross-linking, exploiting the ability of two cysteines
(Cys) residues which are in proximity in space to form disulfide bonds.43 Disulfide cross-linking
has been widely used in studies of protein folding, structure and stability.44, 45 In 2003, thioldisulfide exchange reaction was used to quantitatively explore the thermodynamics of membrane
protein for the first time.46 DeGrado and co-workers reported their application of disulfide crosslinking in measuring the thermodynamics of membrane protein association in detergent micelles.
Their research subject was the transmembrane helix domain of M2 protein from the influenza A
virus, which has been previously shown to self-associate into tetramer, while maintaining its
drug-binding affinity in the meantime.47 Residue 19 in the transmembrane fragment is a cysteine,
which can form disulfide-bonds with Cys19 from another segment when subunit association
occurs. Under reversible redox conditions created by using a buffer containing reduced (GSH)
and oxidized (GSSG) glutathione at the proper ratio, monomer-tetramer equilibrium was
achieved and quantified. Based on those data and further thermodynamic analysis, association
constants for the tetramerization equilibrium in decylphosphocholine (DPC) detergent micelles
were obtained. Five months after this paper was published, the same research group reported that
they had expanded this model system to phospholipid bilayer which better mimicked the natural
membrane as compared to detergent micelles.48 As of today the cross-linking method has been
applied to study membrane protein oligomerization in several other systems including
dimerization of outer membrane phospholipase A and subunits interaction of glycoprotein Ib on
platelets.49, 50
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While these three techniques have been used to study the oligomerization of membrane proteins
in vitro, either in detergent micelles or lipid bilayers, two genetic screen systems, TOXCAT and
GALLEX, have been developed for in vivo studies.51,

52

In those assay systems, the target

transmembrane domain is linked with a specific DNA binding domain of a regulator protein,
which can recognize and bind to specific DNA sequences and regulate the expression of a
downstream reporter product upon dimerization.

TOXCAT was developed by Russ and Engelman in 1999. In their study, the N-terminal DNA
binding domain of ToxR, which is a dimerization-dependent transcriptional activator, and a
transmembrane domain of protein GpA were linked together (Figure 1.4).51, 53 The C-terminal
part of this protein was fused with the maltose binding protein, which functions as a monomeric
periplasmic anchor.

ToxR dimer can bind and activate a reporter gene encoding

chloramphenicol acetyltransferase (CAT). By detecting the expression level of CAT, information
about the strength of GpA TM association can be obtained. For TM mutants whose dimerization
ability are compromised, expression level of CAT decrease significantly, which differentiate
them from native TMs. Thus, residues that play important roles in oligomerization can be
identified. In addition, another application of this strategy is to screen random peptide sequences
libraries for novel oligomerization motifs.54 The advantage of this system is the association of
peptide domains can be detected in natural cell membrane instead of membrane-mimic
environment.
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Figure 1.4 Schematic diagram of mechanism for the TOXCAT assay system. The cytoplasmic
domain of ToxR (labeled as ToxR’) is fused to the N-terminal of the target TM. Maltose binding
protein (MBP) is fused to the C-terminal of the TM. Oligomerization of TM mediates
dimerization of ToxR, which activate expression of CAT at the ctx promoter.
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1.2 Proteolysis in Prokaryotes
1.2.1 The Proteolytic Machinery in Bacteria
A series of chaperone-protease complexes play important roles in general proteolysis and
regulated processive proteolysis.55 These complexes include ClpAP, ClpXP, ClpCP, in which
ClpA, ClpX, ClpC are chaperones.56, 57 These chaperones are AAA+ (abbreviation for ATPases
associated with diverse cellular activities) ATPase which can unfold substrate and translocate it
to the corresponding protease, such as ClpP.58 ClpA is distinguished from ClpX based on their
respective substrate specificity.59 ClpC is a subfamily of ClpA-like proteins.60 Those ATPases
assemble into hexamers, while ClpP composes of two heptamer rings stacking together. The
hexameric ring of ATPase is located on top of the proteolytic chamber entrance of ClpP. With 14
proteolytic active sites inside the chamber, the space can accommodate unfolded proteins as big
as 50 kDa (Figure 1.5).61
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Figure 1.5 Structure of ClpX and ClpP. A. ClpX-ClpP complex. B. Crystal structure of
hexameric ring of ClpX. This image is created from 3hte.pdb. C. Crystal structure of two
superimposed heptameric rings of ClpP (top view), this image is created from 2ce3.pdb. D.
Crystal structure of two superimposed heptameric rings of ClpP (side view), this image is created
from 2ce3.pdb.

Lon is an important protease with functions of protein quality control and cellular physiology
regulation in prokaryotes and eukaryotes, in which the ATPase domain and proteolytic domain
are fused in the same polypeptide chain. It believed that the degradation process is carried on as
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follows. Substrates are firstly recognized by the N-terminal domain, and then unfolded by the
central ATPase domain. After being transported to the C-terminal proteolytic domain by the
ATPase domain, unfolded substrates are finally digested. Although the crystal structure of the
full length Lon protein from bacteria hasn’t been obtained, crystal structures of truncated Lon
and Lon protein from Archaea reveal that Lon protein functions in the form of a hexameric ring.
62, 63

FtsH is an ATP-dependent Zn metalloprotease, which is active in the hexamer state.64 Each
subunit is anchored to the inner membrane by two trans-membrane sequences, while most part of
this protease exists in cytoplasm.65 Both soluble and membrane proteins can be digested by FtsH,
with assistance of specific functional partner proteins.66, 67 The proteolysis process of membrane
proteins can either start from the N-terminus or the C-terminus of the substrates.68 It was found
by Ogura’s research group that the bulky uncharged residue Phe228, which is located around the
central pore of the hexameric ring, is essential for the proteolysis activity.69

One example of an ATP-independent protease is the periplasmic protease DegP. Located in the
periplasm, DegP cannot utilize ATP, which only exists in the cytoplasmic compartment, as the
energy source. It can degrade damaged or denatured proteins in periplasm produced in response
to environmental stress such as heat shock. The protease activity of DegP is exhibited when the
temperature is elevated, while at lower temperature DegP is switched to chaperone activity, and
the proteolytic domain is inactive. The crystal structure presented by Krojer et al. in 2002 has
shown that DegP is a hexamer formed by two trimeric rings with staggered association.70
However, many functional features of DegP cannot be explained by this crystal model. In 2008,
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Krojer et al. reported two different oligomeric states of DegP, 12-mer and 24-mer, by X-ray
crystallography and cryo-electron microscopy (cryo-EM).71 It is proposed that the formation of
the large oligomer cage is induced by the presence of substrates.
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1.2.2 Protein Degradation in Bacteria
Protein level in cells is not simply controlled by transcription or translation. Another important
factor to maintain homeostasis of protein is protein degradation. Different types of abnormal
proteins, like misfolded or denatured proteins, are removed by general proteolysis, which is an
important way to assure protein quality in cells. One example of protein quality control is the
ssrA-tagging system, which is utilized by organisms to dispose of peptides resulting from stalled
biogenesis.72 SsrA tag is a short peptide composed of 11 amino acids, AANDENYALAA.73 SsrA
RNA comes from 10S RNA fraction in E. coli. On one hand, it functions as tRNA, since alanine
is added to it by alanyl-tRNA synthetase. On the other, when mistakes happen during protein
translation, it can function as mRNA and the ssrA tag can be attached to the C-terminus of the
incomplete peptide.74 The addition of the ssrA tag leads to complete degradation of labeled
peptides by specific ATPase-protease complex.

However, purpose of most proteolysis, which is regulated proteolysis, is not just to get rid of
non-functional proteins. It is involved in various cellular processes, like cell growth,
differentiation, signal transduction, stress response, pathogenesis, biofilm formation and protein
secretion etc.75-78 Initiation of proteolysis can be triggered by diverse factors from either the
environment or inside the cell. In the proteolysis of CtsR in B. subtilis, heat shock stimulates
degradation.79 Under normal culture conditions without heat shock, stabilized CtsR inhibits
expression of heat shock genes. When there is a heat shock stimulus, adaptor protein McsB will
bind to CtsR, which leads to conformational change of CtsR.80 Subsequently, CtsR is inactivated
and then digested by ClpCP ATPase/protease complex.81
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One type of intrinsic recognition signal of proteolysis resides at the N-terminus of protein
substrates, which is described as the N-end rule pathway.82, 83 In 1991, Tobias and colleagues
demonstrated that some proteolysis processes in bacteria follow N-end rule pathway.84, 85 They
found that when the N-end residue of a specific protein from bacteria is arginine, lysine, leucine,
phenylalanine, tyrosine or tryptophan, the degradation rate of this protein is greatly accelerated
(half-life ~mins), compared with corresponding protein with other residues at the N-terminus
(half-life ~hours). These amino acids are named destabilizing residues. Among them, leucine,
phenylalanine, tyrosine and tryptophan are primary destabilizing residues, while arginine and
lysine are secondary destabilizing residues. While primary destabilizing residues directly
mediate protein degradation, secondary destabilizing residues recruit a leucyl/phenylalanyltRNA protein transferase (L/F-transferase or Aat) to add primary destabilizing residues leucine
or phenylalanine to the N-terminus.86 In 2007, the Erbse group has found that ClpS is the adaptor,
which binds to the N-terminal destabilizing residues of proteolysis substrates, and then transports
the substrates to the ATPase/protease complex ClpAP for degradation.87 Methionine, which is a
stabilizing residue, is the N-terminal residue for newly-synthesized proteins. Although it can be
removed during co-translational modification by methionine aminopeptidases (MetAPs) if the
second residue has a small side chain, like glycine, cysteine, alanine or serine, the resulted Nterminal residue is still a stabilizing residue.88 This constrains the substrates scope of N-end
pathway proteolysis and ensures that the pathway is a regulated process. The N-end rule
proteolysis can be tightly controlled by the removal of stabilizing residues or addition of
destabilizing residues at the N-terminus.
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In response to diverse stimuli, both degradation signals in substrate proteins can be triggered, or
adaptor proteins will interact with substrate proteins.89-91 These changes can initiate regulated
proteolysis, which either completely breaks down proteins (processive proteolysis) or modify
proteins by partial degradation (non-processive proteolysis).92 One example is the activation of
flagellar gene expression by regulated processive proteolysis of phosphorylated DegU (DegU-P).
93

Bacteria utilize flagella, which whip like appendages, to move through liquids or over solid

surfaces towards nutrients. Flagella-enabled motility plays an important role in pathogenesis of
bacteria.94 In Bacillus subtilis, expression of flagellar filament protein, flagellin, is activated by
proteins SwrA, SwrB and sigma factor sigma D. When sigma D directly interacts with antisigma
factor FlgM in the absence of SwrA and SwrB, expression of flagellin is inhibited. DegU is a
two-component system response regulator transcription factor. It was found that phosphorylated
DegU can activate expression of FlgM, and subsequently inhibit formation of flagella
indirectly.95 Ogura’s research group has demonstrated that DegU-P can be degraded by ClpCP
complex.96 Upon proteolysis, FlgM expression is inhibited and flagellin expression is activated
by sigma D regulation.

Regulated proteolysis is not only used for completely destroying protein, but also utilized by
cells to partially digest target protein and turn it into an active regulatory factor at specific time
and location upon certain signals. PodJ is a scaffolding protein which involved in polar organelle
development in alphaproteobacteria C. crescentus.97 It has two isomers, PodJL is the complete
version and PodJS is the truncated, non-processive proteolysis product, which is anchored to the
membrane. PodJ is a large protein composed of 974 amino acids.98, 99 The structure of PodJ can
be divided into three parts, the cytoplasmic N-terminus, a single transmembrane domain, and
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finally a periplasmic C-terminus portion. At least three proteases are involved in the cascade
proteolysis process of PodJ. First, the periplasmic aspartic protease PerP cleaves the periplasmic
domain of PodJ, leaving the transmembrane domain and cytoplasmic domain.100, 101 Immediately,
intramembrane metalloprotease (IMMP) MmpA degraded the transmembrane portion, which
relieved the cytoplasmic domain PodJS.102 PodJS is required for recruiting polar factors that are
important for pole development after cell division. After cell differentiation, PodJ S is digested by
another protease, which hasn’t been identified so far.103
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1.3 Multidrug Resistance (MDR) of Bacteria
Multidrug resistance is defined as antimicrobial resistance or insensitivity shown by
microorganisms to antimicrobial medicines.104-106 Microorganisms like bacteria, virus, fungi and
parasites all can develop resistance to administrated medicines. Among them, multidrug
resistance of bacteria is most threatening to global public health.107,

108

MDR-associated

worldwide health problem includes, but not limited to spreading and persistence of infections,
especially hospital-acquired infections, increased mortality rates due to infections out of control,
and rising medical research cost, which is aimed to develop novel antimicrobial agents with
diverse targeting mechanisms.109-111

Alexander Fleming has said that there is probably no chemotherapeutic drug to which in suitable
circumstances the bacteria cannot react by in some way acquiring ‘fastness’ resistance.112 MDR
are developed by bacteria through various mechanisms, which can be divided into intrinsic
mechanisms and acquired ones. Intrinsic mechanisms are usually conferred by genes naturally
existing in microorganisms, while acquired mechanisms include MDR-related gene mutations
and transfer of resistance genes carried by mobile genetic materials.113

Antibiotics can be either degraded or chemically modified by certain enzymes, and consequently
lose their activity.114 The genes expressing those enzymes can be obtained by plasmid
transformation, while in some other cases, these genes naturally locate in chromosome of
organisms. Moore et al. found in 2005 by that in Bacteroides fragilis, tetracycline antibiotics can
be hydroxylated by yhe enzyme, flavin-dependent monooxygenase. After hydroxylation, the
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resulting product is not stable at physiological pH and antibiotic activity of the compounds is
lost.115

When drug targets are modified via genetic mutation, the efficiency of antibiotics greatly
decreases.116 One example of MDR resulted from substrate alteration is vancomycin resistance in
Gram-positive cocci.117 Vancomycin acts by binding to the D-Ala-D-Ala C-terminus of the
pentapeptide building block of peptidoglycan, which forms the cell wall of Gram-positive
bacteria.118 Gene mutation or mobile gene transfer produces an enzyme which synthesizes DAla-D-lactate instead of D-Ala-D-Ala. Vancomycin has low affinity to the altered substrate, and
thus the replacement of the terminal Ala by a lactate results in vancomycin resistance in the
microorganism.119

Drug efflux pumps have also played an important role in the development of MDR.120, 121 Drug
efflux pumps in bacteria can be classified according to their energy source or substrate
specificity. Some of these pumps have high specificity of substrate exportation, and only
chemicals with certain structural features can be pumped out of cells, while others are more
promiscuous in terms of efflux substrates. Some efflux proteins need to form complexes with
other proteins to generate a complete transportation system, and can expel a wide range of
structurally unrelated compounds.122,

123

It has been reported that the overexpression of the

multidrug pump system AcrAB-TolC is strongly correlated with fluoroquinolone, ciprofloxacin,
tetracycline resistance in many different MDR strains.124
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1.4 Multidrug Efflux Pumps of Bacteria
Multidrug efflux pumps are membrane protein complexes that actively transport foreign objects
out of cells. The active efflux of these pumps is a critical self-defense mechanism that enables
the survival of bacteria under hostile environments.125, 126 The currently identified drug efflux
pumps can be categorized into five major families, based on their number of transmembrane
domains, type of substrates, and energy sources (Figure 1.6). They are the resistance-nodulationdivision (RND) family, the major facilitator superfamily (MFS), the ATP-binding cassette (ABC)
superfamily, the small multidrug resistance (SMR) family and the multidrug and toxic compound
extrusion (MATE) family.127, 128 Among them, ABC super family is the only primary transporter,
which efflux compounds out of cell upon ATP hydrolysis. Proteins from other families are
secondary porter, whose transportation process is coupled with the electrochemical gradient of
H+ or Na+ across the membrane.129

Figure 1.6 Five major families of multidrug resistant pumps.
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RND family transporters play important roles in MDR resistance of bacteria. Overexpression of
RND pumps has been associated with development of MDR resistance in different strains.130
Deletion of RND transporters makes those strains susceptible to therapeutic antibiotics.131 The
transporters of this family have large periplasmic domains, and always associate with a
periplasmic fusion protein and an outer membrane protein to form a complete efflux channel
spanning the two layer membrane of Gram-negative bacteria to pump a variety of compounds
out of cells, including many antibiotics and chemotherapeutic agents.132 The inner membrane
protein is a drug/proton antiporter, which is responsible of capturing substrate and providing
energy for the whole pump system. The most intensively studied examples of this class are the
AcrAB-TolC tripartite complex in E. coli. and MexAB-OprM in Pseudomonas aeruginosa.133, 134
Besides antibiotics, RND efflux pump is also capable of transporting host derived chemicals
such as bile salts and fatty acids. This efflux allows bacteria to survive in the hostile host
environment.135

MFS is the largest secondary transporter family, containing more than 10,000 proteins with
sequenced genes. These proteins can be categorized into 76 classes, which can be found in all
kindoms of life.136, 137 Each type of MFS transporter can only efflux compounds with certain
structural features. The wide range of their substrates include carbohydrates, lipids, amino acids
and nucleosides, as well as other molecules.138 From the numerous members of MFS family, few
proteins have been intensively investigated, such as E. coli lactose permease LacY, whereas most
of MFS proteins have unknown function.139 Various MFS transporters are involved in different
physiology processes. Some sugar porters in MFS family participate in cellular uptake of glucose
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and polysaccharides, which is important in sustaining metabolism and energy homeostasis in
organisms.140 Structural elucidation of MFS proteins hasn’t matched with the identification of
new proteins. Up to date, only 7 from 6 subfamilies have reported crystal structures. Most of the
proteins have 12 transmembrane helices, and both the N- and C-terminus face the cytoplasm.141

ABC superfamily proteins transport molecules driven by the energy released from ATP
hydrolysis. As a general structural feature, all ABC transporters are composed of 4 domains or
subunits. Two of them are hydrophobic membrane-spanning domains (MSDs), which are
believed to directly constitute the translocation channel across the membrane, whereas the other
two are hydrophilic nucleotide-binding domains (NBDs) which catalyze the hydrolysis of ATP at
the cytoplasmic surface and provide energy for substrates transportation.142,

143

Some ABC

proteins function as efflux pumps, which export proteins related to pathogenesis, or other
compounds like peptide antibiotics and drug. Other ABC proteins serve as bacterial uptake
system with the assistance of a high-affinity solute binding protein, which is located in the
periplasm in Gram-negative bacteria or tethered to the cell surface in Gram-positive bacteria.144,
145

The SMR transporter family has been only found in bacteria. By utilizing the proton motive
force across the membrane, a wide variety of molecules such as cationic detergents, dyes and
antibiotics are extruded out of cell, which confers resistance against those toxic compounds of
bacteria. As implied by the name, SMR proteins are relative small, and composed of about 100140 residues with 4 transmembrane (TM) α-helices spanning the cytoplasmic membrane.146, 147
EmrE is the most studied SMR family member, whose crystal structure indicates that it functions
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as an asymmetrical homodimer (Figure 1.7)148. TM helix 1 (TM 1) and TM helix 3 (TM3) of
each monomer constitute the substrate binding pocket within the membrane, whereas the
interaction between TM 4’s of different monomers are associated with the dimer formation.
Glu14 is the key residue, which is conserved in most SMR proteins.149 It plays major role in
recognizing cationic substrates, and also in facilitating entrance of protons during efflux.

Figure 1.7 Asymmetrical homodimer of EmrE.

Proteins from multidrug and toxic compound extrusion (MATE) family can be found not only in
prokaryotes, but also in eukaryotes, like yeasts, fungi, plants and mammals. The presence of a
MATE transporter in bacteria was reported to correlate with resistance to tigecycline, which is a
new glycylcycline-class antibiotic.150 The substrate transportation mechanism of MATE protein
is thought to be coupled with the antiport of Na+ across the membrane. The first MATE-type
transporter is NorM, which was identified and reported by Morita et al. in 1998.151 Although
more MATE proteins have been characterized, there is no apparent conserved peptide sequence
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for the majority of MATE transporters. They have about 40% similarity, which suggests an
overall conserved structure and function. Most of them are around 400-500 amino acids long,
and have 12 transmembrane helices.152 In 2010, He et al. published a crystal structure of NorM
from Vibrio cholerea, showing that the protein has an outward-facing conformation, and a
cation-binding site was identified in proximity to transportation relevant residues. The proposed
transportation mechanism is the binding of cation from extracellular environment induces the
outward-facing conformation changing to inward-facing conformation. Substrate binding causes
the conformation changing back to outward-facing, allowing substrates exportation (Figure
1.8).153

Figure 1.8 Proposed drug transportation mechanism of NorM protein. Cation (green) binding
induces outward-facing conformation changing to inward-facing conformation. Cation is
26

released in cytoplasm and drug compounds from the cytoplasm bind to the transport protein,
which changes conformation to outward-facing. And the bound drug molecules are released into
the extracellular space.
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1.5 Introduction of AcrB
Escherichia coli thrive in the intestinal tract, where there are high concentrations of bile salts.
Bile salts are toxic to cells at high concentration.154 Enteric flora E. coli can survive at a bile salt
concentration as high as 20 mM. It is initially thought that the outer-membrane of Gram-negative
bacteria could prevent the influx of the destructive compounds.155 In 1997 Nikaido and
coworkers discovered that the active efflux transporter AcrB, which is located in the inner
membrane of E. coli, plays an important role in the resistance.156 In addition to bile salts, AcrB
transports a broad range of compounds, including cationic dyes like crystal violet, ethidium
bromide, rhodamine 6G, antibiotics like novobiocin, tetracyclines, penicillins, and detergents
like Triton X-100 and sodium dodecylsulfate (Figure 1.9).157 Active efflux by AcrB and its
homologues is critical for multidrug resistance in Gram-negative bacteria.158

Efflux pump AcrB is a member of the Resistance-Nodulation-Division (RND) super family.159 In
E. coli, it associates with periplasmic protein AcrA, which belongs to the Membrane Fusion
Protein family (MFP), and outer membrane channel TolC to form a tripartite complex that spans
the inner membrane, periplasmic space, and outer membrane of an E. coli cell (Figure 1.10). This
tripartite complex extrudes a variety of noxious compounds out of cell from both the cytoplasm
and the periplasm. In this complex, AcrB is the component that binds substrate first and
transports substrates through a ‘channel-tunnel’ formed by docking with TolC out into external
environment.160 AcrA is a periplasmic protein which nearly spans the entire periplasm and
presumably assists the tight interaction between AcrB and TolC.

28

Figure 1.9 Selected substrates of the AcrA-AcrB-TolC efflux system.
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Figure 1.10 Docking structural model and drug efflux mechanism of AcrA-AcrB-TolC tripartite
complex. AcrA is represented by dotted ovals in the left model. Reprinted by permission from
Macmillan Publishers Ltd: Nature (Murakami, S., Nakashima, R., Yamashita, E., and
Yamaguchi, A. Crystal structure of bacterial multidrug efflux transporter AcrB, 419, 587-593)
©2002.

AcrB functions as a trimer, containing three identical subunits of 1049 residues. Murakami et al.
determined the first crystal structure of AcrB in 2002 at 3.5 Å resolution.160 The entire
architecture can be divided into 3 parts. The bottom part is a transmembrane domain containing
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twelve transmembrane alpha-helices from each protomer. Transmembrane domains from three
protomers form a central channel spanning the entire inner membrane and link to the pore
structure in the periplasm (Figure 1.10). The section immediately above the transmembrane
domain and located in periplasm is the pore domain. Each protomer is composed of four
subdomains, each of which is a complex of beta-strands and alpha-helices. In the middle of the
trimer, each protomer contributes an alpha-helix, forming the pore structure as mentioned above
(Figure 1.11). Between the pore domains of neighboring subunits, there is a tunnel called the
vestibule which connects the bottom of the pore to the periplasm. It has been proposed to be a
pathway for substrates in the periplasm to enter the pore. The TolC docking domain is above the
pore domain and presumably connects TolC with AcrB. Each docking domain has two mixedbeta-sheet subdomains. And the docking domains from all three protomers together form a
funnel-like structure. The diameter of the top of the funnel is very close to that of the bottom of
TolC. Each docking domain possesses a hairpin structure which inserts into the neighboring
protomer and this hairpin structure is critical to the interaction between adjacent protomers
(Figure 1.12).
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Figure 1.11 Topology diagram of an AcrB protomer showing the secondary structure elements.
Cylinders and arrows are alpha-helices and beta-strands, respectively. Definition of different
domains and position of the inner membrane were shown. Reprinted by permission from
Macmillan Publishers Ltd: Nature (Murakami, S., Nakashima, R., Yamashita, E., and
Yamaguchi, A. Crystal structure of bacterial multidrug efflux transporter AcrB, 419, 587-593)
©2002.
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Figure 1.12 Top view of an AcrB trimer in ribbon representation. Each protomer is individually
colored. The red arrows show the hairpins critical for trimerization. The red circle depicted the
pore structure formed by three alpha-helices, each contributed by one protomer. This image is
created from 2GIF.pdb.

In 2006, Murakami et al. determined the crystal structure of AcrB bound with substrates, which
has provided researchers a foundation to speculate the transport mechanism of AcrB.161
Conformations of the three protomers in an AcrB trimer are distinctively different. Only one
protomer binds substrate, even when the concentration of drug reaches saturation in the cocrystallization system. And there are also conformational differences between the other two
protomers. Researchers have proposed a three-step rotary mechanism for AcrB, in which each
protomer is in a different state at any time of transportation: access, binding, and extrusion
(Figure 1.13).130,

161, 162

During the transportation process, each protomer cycles through the
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access, binding, and extrusion states sequentially, and then goes back to the access state. In the
access state, the vestibule is open and the substrate has access to it. In the binding state, the
binding pocket in the protomer expands so that it has enough space to accommodate a substrate.
Finally protomer bound with a substrate rotates into the extrusion state, when vestibule is closed
and the exit pass is open. The substrate is released into the funnel structure of TolC docking
domain of AcrB.

The structure and function of AcrB has been the subject of many studies. While the efflux
mechanism, interaction with AcrA/TolC, and substrate binding and translocation pathway of
AcrB have been thoroughly investigated, little is known about its oligomerization process. AcrB
is an obligate trimer, existing and functioning exclusively as a trimer.161 The trimerization
process of AcrB is an indispensable component for the understanding of AcrB facilitated drug
resistance, and yet little work has been done to elucidate this process.

Figure 1.13 Schematic diagram of the proposed three-step rotatary drug efflux mechanism of
AcrB (top view). Entrance and exit of each protomer are depicted as red lines. Dotted lines
represent the drug binding pocket and the translocation pathway. Small hexagons represent
substrates. Reprinted by permission from Macmillan Publishers Ltd: Nature (Murakami, S.,
34

Nakashima, R., Yamashita, E., Matsumoto, T. and Yamaguchi, A. Crystal structure of a
multidrug transporter reveal a functionally rotating mechanism, 443, 173-179) ©2006.
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Chapter II Assembly of AcrB Trimer in Cell Membrane

2.1 Introduction
Biotinylation is a reaction to attach biotin covalently to proteins. It is a widely used protein
labeling method for the purpose of protein detection, immobilization and purification.163 In
nature, biotinylation occurs as a type of post-translational modification, which is catalyzed by
biotin ligase, also known as Biotin Holoenzyme Synthetase (BHS). During this process, biotin is
attached to a natural substrate through the formation of an amide linkage between biotin carboxyl
group and the epsilon-amino group of a specific lysine residue (Figure 2.1).164 In 1999, a 15residue peptide was reported by Schatz group as a minimal substrate for BHS with comparable
biotinylation

kinetics

as

natural

substrate.

The

sequence

of

this

15-mer

is

GLNDIFEAQKIEWHE, and is named the avitag. The avitag can be fused at either N-terminus or
C-terminus of the target protein.
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With advantages of small size and high efficiency of

biotinylation, the avitag becomes a widely used protein tag which can serve a variety of purposes,
such as protein purification, detection and immobilization. In this study, I fused the avitag at the
C-terminus of AcrB as a specific marker in the study of monomer co-assembly in the cell
membrane.
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Figure 2.1 The biotin protein ligase (BPL) reaction. Reprinted from Trends in Biochemical
Sciences, 24, Chapman-Smith, A. and Cronan Jr., J. E., The enzymatic biotinylation of proteins:
a post-translational modification of exceptional specificity, 359-363, Copyright (1999), with
permission from Elsevier.

As discussed in the previous chapter, oligomerization is a dominant phenomenon in protein
structure due to its several functional advantages over monomers.3 For example, oligomers can
adopt a variety of symmetrical structures to provide specific morphological functions.166
Cooperativity of oligomeric proteins, including allosteric regulation and multivalent binding, as
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well as equilibration between monomer and oligomer serves as a mechanism for activity
regulation.167, 168 Although bioinformatics studies reveal that around 35% of proteins exist and
function as oligomers instead of monomers, the process by which monomers assembling into
oligomers in the cell is poorly understood.1,

169

By studying the oligomerization of inner

membrane protein AcrB, our group has previous found that individual subunits of AcrB folded
before oligomerization, and monomer folding and trimerization were two sequential steps.170 In
the following study, another aspect of the oligomerization of AcrB homo-trimer has been
investigated. This research answers the questions, how do monomeric subunits of AcrB form
trimers, and whether the assembling is a completely random process or does it follow any other
rules. To answer these questions, AcrB constructs with different tags were designed and
expressed in the same cell, and then their co-assembling behavior was studied.
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2.2 Materials and Methods
2.2.1 Materials
Protein molecular weight marker (Spectra Multicolor High Range Protein Ladder) for SDSPAGE was from Thermo (Rockford, IL). The custom polyclonal rabbit anti-AcrB antibody was
obtained from GenScript (Piscataway, NJ).170 All enzymes for nucleic acid manipulation were
from New England Biolabs (Ipswich, MA) and all the chemicals from BioWorld (Dublin, OH).
The parent wild-type (BW25113) and AcrB deficient ΔacrB strains were obtained from the Yale
Coli genetic stock center. The ΔacrB strain lacks the chromosomal acrB gene and is kanamycin
resistant.

2.2.2 Cloning, expression and purification of AcrB and its mutants
The gene encoding AcrB was amplified through Polymerase Chain Reaction (PCR) from
template E. coli genomic DNA. After PCR, amplified AcrB genes were inserted into pBAD33
between digestion sites XbaI and HindIII, or into pAC5 between SacI and HindIII, respectively.

Protein coding sequences in all plasmids used in this study were confirmed by DNA sequencing.
Plasmid pBAD33-AcrBhistag and pAC5-AcrBavitag were then transformed respectively into an E.
coli strain deficient in gene acrB (BW25113ΔacrB) for protein expression. Bacteria containing
plasmid pBAD33-AcrBhistag were cultured at 37 °C in Lysogeny Broth (LB) media with 50
g/mL kanamycin and 25 g/mL chloramphenicol, while bacteria containing plasmid pAC5AcrBavitag with 50 g/mL kanamycin and 100 g/mL ampicillin. Co-transformed bacteria
containing both plasmid pBAD33-AcrBhistag and pAC5-AcrBavitag were cultured at 37 °C in LB
media with 50 g/mL kanamycin, 25 g/mL chloramphenicol and 100 g/mL ampicillin. The
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same ampicillin and kanamycin concentrations were used throughout the study, unless otherwise
noted. After overnight culture, cells were harvested by centrifugation at 7,000×g for 10 min at
4 °C. Bacterial cells were used immediately for purification.

AcrBhistag was purified using metal affinity chromatography as described.171 Briefly, the cell
pellet was resuspended in a lysis buffer (30 mM sodium phosphate buffer solution (NaPi), 0.5 M
NaCl, 10% glycerol, 1mM phenylmethylsulfonyl fluoride (PMSF), pH 7.5) and then sonicated
using a Fisher Scientific Sonicator Dismembrator (MODEL 150E) on ice for 20 min with 5 sec
on/off intervals and 75% amplitude to break the cells. After centrifuged at 15,000×g for 20 min
at 4 °C, the supernatant containing soluble proteins were discarded, while the precipitant which
contains the membrane was re-suspended in an extraction buffer (30 mM NaPi, 0.5 M NaCl, 10%
glycerol, 1% Triton X-100, pH 7.5) and then shaken on ice for 2 h. The extraction mixture was
then centrifuged at 15,000×g for 20 min at 4 °C. AcrB was recovered in the supernatant.
Imidazole was added in the supernatant (pH~7.5) to a final concentration of 10 mM and the
supernatant was incubated with nickel-nitriloacetic acid (Ni-NTA) resin at 4 °C for 45 min. After
incubation, the supernatant-resin mixture was loaded to a column, washed using a buffer
containing the indicated concentration of imidazole (30 mM NaPi, 0.5 M NaCl, 10% glycerol, 1%
triton, 10-100 mM imidazole, pH 7.5) and eluted using an elution buffer (30 mM NaPi, 0.5 M
NaCl, 10% glycerol, 0.03% n-Dodecyl β-D-Maltopyranoside (DDM), 200 mM imidazole, pH
7.5). Purified protein was analyzed in sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and visualized using Coomassie Blue staining.
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2.2.3 Drug susceptibility assay
AcrB activity was measured using a drug susceptibility assay.172 E. coli strain BW25113ΔacrB
was used as the host cell. BW25113ΔacrB strains transformed with plasmid pQE70-AcrB or the
empty vector pQE70 were used as positive and negative controls, respectively. Freshly
transformed cells were plated on LB agarose plates containing the corresponding antibiotics. A
single colony was used to inoculate a LB media. The exponential-phase cultures of different
strains were diluted to an OD600nm unit of 0.1 using LB broth. 5 µL of this culture was used to
inoculate 2 mL of LB media containing the indicated concentration of erythromycin or
novobiocin. The cultures were incubated with shaking at 37 °C overnight. The next morning,
OD600nm of each sample was measured. The lowest concentration of drug that completely
inhibited the growth of bacteria was recorded as the minimum inhibitory concentration (MIC).
Each experiment was repeated at least three times.

2.2.4 Analysis of expression levels of AcrB by immunoblotting
Freshly transformed colonies of BW25113ΔacrB containing plasmid pBAD33-AcrBhistag or
pAC5-AcrBavitag were used to inoculate LB medium containing proper antibiotics. After
culturing at 37 °C overnight, cells were harvested by centrifugation at 7,000×g for 10 min at 4 °C,
and then resuspended in a lysis buffer (30 mM NaPi, 0.5 M NaCl, 10% glycerol, 1mM PMSF,
pH 7.5) to an OD600nm of 15. Equal volumes of the re-suspended solution were withdrawn and
sonicate on ice for 20 min with 5 sec on/off intervals and 75% amplitude to lyse the cells. After
centrifugation at 15,000×g for 20 min at 4 °C, the supernatant containing soluble proteins were
discarded. The cell paste containing membrane vesicles was re-suspended in an extraction buffer
(30 mM NaPi, 0.5 M NaCl, 10% glycerol, 1% Triton X-100, pH 7.5) and then was shaken on ice
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for 2 h. The extraction mixture was then centrifuged at 15,000×g for 20 min at 4 °C. AcrB was
extracted into the supernatant. SDS-Loading buffer was then added into the samples. The
samples were resolved using SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF)
membrane for Western blot analysis using a polyclonal rabbit anti-AcrB primary antibody and an
alkaline phosphatase-conjugated anti-rabbit secondary antibody. Protein-antibody conjugates
were visualized using substrates Nitro blue tetrazolium chloride (NBT) and 5-bromo-4-chloro3’-indoyl phosphate p-toluidine (BCIP).

2.2.5 Determination of the biotinylation level of AcrB
A standard sample, AcrBhistag-avitag, was first purified as described above. This AcrB construct
contains both histag and avitag, in which a stretch of 30 residues containing
LEHHHHHHSGGGSGGGLNDIFEAQKIEWHE was added to the C-terminal of AcrB. The
corresponding plasmid, pBAD-AcrBhistag-avitag, was transformed into BW25113ΔacrB for protein
expression. The presence of the avitag did not interfere with the purification of the protein
through the histag. The biotinylation level of purified AcrBhistag-avitag was determined using a
commercial biotinylation quantification kit (Pierce Biotin Quantitation Kit).173, 174

Next, we used a mixture of purified AcrBhistag-avitag and AcrBhistag to create a calibration plot. For
this plot, a series of standard solutions were made, each contained the same amount of AcrB, but
with an increasing ratio of AcrBhistag-avitag to AcrBhistag (Figure 2.2). The samples were subjected
to anti-AcrB Western blotting and anti-Biotin Western blotting. All samples have bands of the
same intensity in anti-AcrB Western Blotting, while in anti-biotin Western blotting an increase
of band intensity was observed due to the increase of AcrBhistag-avitag portion.
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Figure 2.2 Schematic diagram of the biotinylation level measurement. A series of standard
solutions with increasing percentage of AcrBhistag-avitag were prepared. In anti-biotin Western blot,
standard solution with higher AcrBhistag-avitag% showed more intense band. By comparing band
intensity of protein sample with the ladder, its AcrBavitag% can be estimated. Blue represents
AcrB without biotinylation (AcrBhistag), and yellow represents AcrB with biotinylation
(AcrBhistag-avitag in standards and AcrBavitag in the unknown sample).

To determine the level of biotinylation in co-expressing strains, detergent was used to extract
AcrB from co-transformation strain. Before loading AcrB sample on gel, AcrB concentration
was adjusted to the same level as the concentration in standard samples. In anti-biotin Western
blot, band intensity comparison revealed the percentage of AcrBavitag in crude membrane
extraction. Biotinylation level of purified AcrB was determined similarly.
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2.3 Results and Discussions
2.3.1 Drug tolerance of strains BW25113acrB containing plasmid pBAD-AcrBhistag or
pAC5-AcrBavitag
To examine if the introduction of the fusion tags at the C-terminus affects the structure and
function of AcrB, we tested the drug susceptibility of an acrB gene knockout strain containing
these plasmids. In addition to the two strains containing these plasmids, strain BW25113acrB
with no plasmid and with plasmid encoding wild-type AcrB (pET22b-AcrB) were used as
negative and positive controls, respectively. MIC data were summarized in Table 2.1.

Table 2.1 MIC of BW25113acrB transformed with different plasmids (g/ml).
Ery

Nov

R6G

TPP

No plasmid

2

5

5

5

pET22b-AcrB

80

320

640

640

pBAD-AcrBhistag

80

320

640

640

pAC5-AcrBavitag

80

320

640

640

It can be seen that strain BW25113acrB-pBAD33-AcrBhistag and BW25113acrB-pAC5AcrBavitag both had the same MIC as the positive control, indicating that these two AcrB
constructs were fully active.

2.3.2 Expression level of AcrB in two plasmids
The relative expression level of AcrBhistag and AcrBavitag was determined through anti-AcrB
Western blot analysis (Figure 2.2). Under the same experimental condition, the band intensity of
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AcrBhistag was twice the intensity of AcrBavitag. Therefore, the relative expression level of AcrB
from pBAD33-AcrBhistag is twice the expression level from pAC5-AcrBavitag.

Figure 2.3 Anti-AcrB Western blot image shows relative expression level for two plasmids,
pBAD33-AcrBhistag (left lane), pAC5-AcrBavitag (right lane).

If the assembly of AcrB subunits follows a total random pattern, the abundance of hybrid trimers
and pure trimers should follow the statistical analysis as shown in Figure 2.4.

Figure 2.4 Statistical analysis of the expected distribution of co-assembling of co-expressed
AcrB subunits based on the random mixing mechanism. “r” is the relative expression level of
AcrB from one gene source (e.g., the genomic DNA or plasmid #1, white circles) over the other
gene source (e.g., plasmid #2, gray circles) in the experimental system. If trimerization in the cell
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membrane is completely random, then r3/(r+1)3 of all trimers will contain three white subunits,
and 1/(r+1)3 of all trimers will contain three gray subunits. The other trimers will contain either
two gray subunits [3r/(r+1)3] or two white subunits [3r2/(r+1)3]. The corresponding fractions for
each species are calculated for cases when r equals to 1, 3, 4, 8, or 16.

According to the analysis shown in Figure 2.4, white circles are AcrBhistag, grey circles are
AcrBavitag, and the r value is 2. The relative abundance of pure trimers (AcrBhistag)3, (AcrBavitag)3,
and hybrid trimers (AcrBhistag)2(AcrBavitag)1 and (AcrBhistag)1(AcrBavitag)2 are 8, 1 and 12, 6,
respectively. If there are 27 trimers overall, 8 of them are pure AcrBhistag trimer, 12 of them
contain 2 AcrBhistag subunits each trimer, and 6 of them have 1 AcrBhistag subunit each trimer,
only 1 is a pure AcrBhistag trimer (Figure 2.4). Thus, through examining the relative abundance of
pure and mix trimer, we would be able to test if the random assembly model is correct.

Proteins extracted from a strain co-expressing AcrBavitag and AcrBhistag were subjected to metal
affinity purification. Before purification, the overall level of biotinylation depends on the
intrinsic expression level of each type of subunits. Since the expression level of AcrBhistag was
twice of the expression level of AcrBavitag, the expected percentage of the biotinylated AcrB was
~33%. When the AcrB sample was subjected to purification using metal affinity chromatography,
only trimers containing at least one AcrBhistag subunit would bind to the column and be purified.
Therefore, (AcrBavitag)3 would be lost. However, since it only accounted for 1/27 of the overall
number of trimers, the final biotinylation level of the purified sample would not be affected too
much and drop slightly to ~31% (Figure 2.5). Based on this analysis, if the assembly of trimers is
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completely random, we expect the level of biotinylation of the sample to remain roughly the
same before and after purification.

Figure 2.5 Schematic illustration of the co-expression of AcrBhistag and AcrBavitag. The relative
expression level of AcrBhistag to AcrBavitag is 2 to 1. Assuming subunits randomly co-assemble
into trimers, among 27 trimers, statistically there will be 8, 12, 6, and 1 trimers that contain 3, 2,
1, or 0 AcrBhistag. The overall biotinylation level is 33%. Once purified using metal affinity
chromatography, only trimers containing at least one AcrBhistag would be retained. Therefore, 31%
of subunits should be biotinylated in purified samples.

2.3.3 Identification of proper washing and elution condition for AcrBhistag and AcrBavitag
AcrB has a low level of intrinsic affinity to Ni-NTA resin. To find the proper imidazole
concentration that selectively elute AcrBavitag or AcrBhistag, I performed step-wise elution using
20 bed volume (BV) of 10 mM, 10 BV of 50 mM, 2 BV of 100 mM and 6 BV of 500 mM
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imidazole in PBS buffer (30 mM phosphate buffer, 200 mM NaCl, pH 7.5). The eluent was
collected in 1 mL (2 bed volume) fractions. The first fraction at 10 mM, the first and last
fractions at 50 mM, as well as fractions at 100 and 500 mM imidazole were analyzed using SDSPAGE (Figure 2.5).

Figure 2.6 showed the representative washing-elution patterns of AcrBhistag and AcrBhistag-avitag.
Two conclusions can be drawn based on these results. First, the presence of the avitag sequence
at the C-terminal of the histag did not affect the binding and purification of the protein using
metal affinity chromatography. Second, PBS buffer containing 10 and 50 mM imidazole did not
wash off a significant amount of AcrBhistag. Buffer containing 100 mM imidazole eluted a
significant amount of AcrB, while the majority of AcrB were eluted at 500 mM imidazole.
Purified AcrBhistag and AcrBhistag-avitag were adjusted to the same concentration, and then mixed at
different ratio to establish a series of standard solutions and used in the determination of
biotinylation level.

A.

B.
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Figure 2.6 A. Gradient washing and elution of AcrBhistag. B. Gradient washing and elution of
AcrBhistag-avitag.

2.3.4 Elution patterns of AcrB from co-expression
As discussed above, the biotinylation level of purified AcrB from BW25113acrB containing
both plasmids pBAD-AcrBhistag and pAC5-AcrBavitag could be used to verify the random
assembly model. We loaded membrane vesicles extracted from BW25113acrB co-expressing
AcrBhistag and AcrBavitag to the column and eluted following the steps of 10 bed volumes of 10
mM, 10 bed volumes of 50 mM, 2 bed volumes of 100 mM, 2 bed volumes of 200 mM, and
finally 2 bed volume of 500 mM imidazole. Eluent was collected in 1 mL (2 bed volume)
fractions. The first fraction at 10 mM, the first and last fractions at 50 mM, as well as fractions at
100, 200, and 500 mM imidazole were analyzed using SDS-PAGE (Figure 2.7A). The major
elution fraction occurred at 50 mM-1, while the relative intensity of this band was weaker than
the corresponding band in AcrBavitag purified alone. In addition, proteins could be detected in all
elution fractions, while the 200 mM fraction was slightly stronger than the 100 mM fraction.

We also tested the co-purification of these two proteins by mixing membrane vesicles extracted
from BW25113acrB expressing either AcrBhistag or AcrBavitag, which was immediately subjected
to metal affinity purification (Figure 2.7B). In this case while both fusion proteins existed in the
solution, we believe they did not exchange subunits in the time scale (~1 h) of purification.
Consistent with our expectation, there was no detectable difference in the result of purification
when the mixture was equilibrated for 2 h before purification. The mixture was purified and
eluted under the same condition as described above. The elution pattern was drastically different
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from that of the co-expressed sample. The predominant band appeared at 200 mM imidazole,
similar as AcrBhistag purified alone. In addition, weak bands could be observed in 50 mM elution
fractions, which were likely AcrBavitag. The band intensity of the first fraction of 50 mM elution
(50 mM-1) was weaker than the corresponding band in AcrBavitag purified alone, which could be
a result of competitive binding between AcrBhistag and AcrBavitag to the resin.

A.

B.
Figure 2.7 A. Gradient elution of co-expressed AcrBhistag and AcrBavitag. B. Gradient elution of
co-purified AcrBhistag and AcrBavitag individually expressed and mixed after extraction.

2.3.5 AcrBavitag in co-expressed samples was retained longer on Ni-NTA resin than
AcrBavitag in mixed samples
Different elution patterns indicated that AcrB trimer composition of co-expressed sample was
different from that of the simply mixed sample. The relative amounts of AcrBavitag and AcrBhistag
in each elution fraction were determined using anti-biotin Western blot. As described previously,
concentrations of purified AcrBhistag and AcrBhistag-avitag were adjusted to be the same using SDS50

PAGE. By mixing two types of protein with different volume ratio, a series of standard solutions
were made, in which AcrBavitag% increased gradually (at the same time, AcrBhistag% decreased).
In anti-biotin Western blot membrane, the series of standard samples generated a band pattern in
which band intensity is getting higher when moving from low AcrBavitag% to high.

To determine the relative AcrBavitag% in each elusion fraction, the AcrB concentration of the
samples were adjusted to be the same as the standards. From anti-biotin Western blotting,
AcrBavitag% can be estimated by comparing band intensity of samples to the standards. Figure
2.7A showed that in aliquots samples from co-transformed strain, AcrBavitag existed at similar
levels in all samples (from low imidazole concentration washing to high imidazole concentration
elution). Since the bands intensity decreased gradually from washing sample to elution (Figure
2.7B), it means AcrBavitag% decreased from 50 mM imidazole wash (similar intensity as 70%
ladder) to 200 mM imidazole elution (less intense than 30% ladder).
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A.

B.
Figure 2.8 A. Anti-biotin Western blot for determining AcrBavitag% in purified AcrB from coexpression. B. Anti-biotin Western blot bands intensity analysis by software imageJ.
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For the control sample, in which individually expressed AcrBhistag and AcrBavitag was mixed
before purification as described above, the pattern of biotinylation was completely different. As
shown in Figure 2.9, no biotinylation was detected for samples eluted at 200 mM and 500 mM
imidazole, indicating that AcrBavitag% in elution aliquots were too low to be detected by antibiotin immunoassay. For the sample eluted at 50 mM imidazole, AcrBavitag% was close to 100%.
The concentration of AcrBavitag decreased dramatically in the sample eluted at 100 mM imidazole.

Figure 2.9 Anti-biotin Western blot for determining AcrBavitag% in purified AcrB from a mixture
of individually expressed AcrBhistag and AcrBavitag.

In the co-purification case, membrane extractions containing individually expressed AcrBhistag or
AcrBavitag were mixed right before purification. Since no time was allowed for subunit exchange,
there should just be pure AcrBhistag trimers and AcrBavitag trimers. The anti-biotin Western blot
result (Figure 2.8) showed that the binding between pure AcrBavitag trimer and Ni-beads was
weak and the majority of proteins could be effectively eluted using a buffer containing 50 mM
imidazole. The small amount of leftover AcrBavitag could be completely eluted by the buffer
containing 100 mM imidazole. The difference between the biotinylation patterns as shown in
Figure 2.7A and 2.8 indicated that AcrBavitag associate with AcrBhistag to form hetero-trimer
during co-expression. These hybrid trimers had different AcrBavitag/AcrBhistag ratios, and thus had
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different affinities with Ni-NTA. In summary, co-assembly process of AcrB did occur in cells
with two AcrB gene sources based on data obtained so far.

In the above analysis, we assumed that all AcrBavitag subunits were biotinylated for the
simplification of discussion. However, the reference point for comparison in this study was the
relative levels of biotinylation of the sample in crude membrane extracts, as well as in sequential
washing/ elution fractions during metal affinity purification. Therefore, the absolute level of
biotinylation of AcrBavitag would not affect the interpretation of the experimental result.

2.3.6 Assembly of AcrB trimer is not completely random
By comparing anti-biotin Western blot band patterns of co-transformed strain with that of
extraction mixture, we can conclude that co-assembly of AcrBavitag and AcrBhistag happened
during co-expression. But whether the co-assembly process follows the random assembly model
remains unclear. Previous data and analysis have shown that the relative expression level from
pBAD33-AcrBhistag and pAC5-AcrBavitag was around 2:1. If AcrB from two gene sources were
randomly co-assembled, only pure AcrBavitag trimer would be washed off Ni-NTA at imidazole
concentration less than 100 mM, while hybrid trimers and pure his-trimers would remain bound
until the imidazole concentration rose to 200 mM. According to the random co-assembly model,
AcrBavitag% in these elution aliquots should be around 31% (Figure 2.4) which was close to the
AcrBavitag% of crude membrane extraction before Ni-NTA purification (33%).

To test this assumption, AcrBavitag% in crude membrane extraction of co-expressed sample was
determined (Figure 2.10). Through comparing AcrBavitag% in detergent extracts with the
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standards, AcrBavitag% was estimated to be 30%. This result was consistent with the observation
that the expression level ratio of AcrBhistag to AcrBavitag was approximately 2 to1.

Figure 2.10 Anti-biotin Western blot image for determining AcrBavitag% in detergent extraction
of co-expressed sample before purification.

Similarly, the percentage of AcrBavitag was determined for the elution fraction at 200 mM
imidazole. As shown in Figure 2.11, AcrBavitag% was around 5%-10%. This difference indicated
that AcrB trimer assembly was not completely random.

Figure 2.11 Anti-biotin Western blot image for determining AcrBavitag% in the 200 mM
imidazole elution fraction of co-expressed sample.
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2.4 Conclusions
As a summary, based on the above results as well as several other experiments performed by
other members of our group, we conclude: 1) co-assembly of AcrB from different gene sources
occurs, but not in a random fashion, and 2) the formation of pure trimer is favored. How could
the formation of pure trimer be initially favored? One possible explanation for this preference is
the “clustering effect” (Figure 2.12). Ribosomes are known to form polysomes where multiple
ribosomes translate a single mRNA simultaneously, resembling a chain of pearls when
visualized under an electron microscope (EM).175 When two AcrB variants are expressed
together in the same cell (Figure 2.12, red and blue), the structure of polysome determines that
subunits of the same type would present at high concentration at the site of production. The
elevated concentration of a specific type of subunit favors the formation of pure trimers. Hybrid
trimer forms when two polysomes translating different types of subunits happen to locate close
to each other, or when monomers diffuse away from its site of production. In addition, AcrB
trimers associate/dissociate and equilibrate between pure and hybrid trimers in the cell
membrane. The clustering of nascent monomers could also explain the lack of free monomers in
the cell membrane—for obligate oligomers such as AcrB, monomers or assembling intermediate
multimers are rarely observed. Due to the clustering of ribosomes in a polysome, multiple copies
of monomers are made close to each other both in time and space, which greatly promoted the
efficiency of oligomerization. Therefore, the majority of nascent monomers could have
assembled into trimers before leaving their birthplace.
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Figure 2.12 Hypothesis of the clustering effect during the production of AcrB trimers.
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Chapter III Measurement of Membrane Protein AcrB Trimerization in Cells by the
GALLEX System

3.1 Introduction
GALLEX is a genetic screening system which has been used to study protein oligomerization in
vivo.51, 176 In the GALLEX assay system, the target transmembrane domain is linked with a
specific DNA binding domain of a regulator protein LexA, which can recognize and bind to
specific DNA sequences and regulate the expression of a downstream reporter product upon
dimerization.177 LexA acts as a transcription suppressor that negatively regulates the
transcription of many different genes in Escherichia coli in its dimer form.178-179 Structure of
LexA contains a C-terminal dimerization domain and an N-terminal DNA binding domain
(LexA DBD) which does not contribute to dimerization (Figure 3.1).180-182 As early as 1995, the
Schnarr group fused the LexA DBD to the protein Fos to investigate the homo-dimerization
capability of Fos variants.183 Dimerized LexA DBD can recognize an op+/op+ operator sequence
which controls the transcription of chromosomal lacZ gene in an engineered strain. When homoassociation of target protein occurs, LexA DBDs are pulled together and dimerize.52 Then
dimerized LexA DBDs bind to op+/op+ operator and repress transcription of lacZ. Subsequently,
activity of beta-galactosidase decreases.184 In this system, protein homo-oligomerization can be
measured by testing the activity of beta-galactosidase.
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Figure 3.1 Structure of LexA. N-terminal DNA binding domain is colored in red. C-terminal
domain is colored in green. Short hinge region linking N-terminal and C-terminal domains is
colored in blue (Created from 1JHF.pdb). 185

To further expand the LexA system to study hetero-oligomerization of proteins, the same group
has developed a more advanced system in which two LexA derivatives with different DNA
binding specificities are employed.186 Wild-type LexA recognizes the original sequence (op+),
while the recognition sequence of LexA408 variant is an altered operator (op408). Then a
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reporter strain (SU202) is constructed in which the chromosomal lacZ gene is under the control
of an op+/op408 hybrid operator. Hetero-oligomerization of proteins fused to wild-type LexA
and LexA408 can be then detected by monitoring the repression of lacZ gene (Figure 3.2).

Figure 3.2 Schematic diagram of transcriptional repression of lacZ gene by LexA dimer. In
homodimerization assay, expression of the lacZ gene in strain SU101 is driven by a promoter
under the control of an operator (op+/op+). In heterodimerization assay, expression of the lacZ
gene in strain SU202 is driven by a promoter that under the control of a mixed operator
(op+/op408). When dimerized LexA bind to corresponding operator, transcription of the lacZ
gene is repressed, resulting in activity decrease of beta-galactosidase.

In 2002, this LexA assay system was applied to explore interaction of transmembrane protein by
the Engelman group and named the GALLEX system.52 In their study, the glycophorin A
transmembrane domain (GpA TX helix) was linked either with the wild-type or the mutant LexA
DBD and transformed into strain SU101 or SU202 for homo-dimerization or hetero-dimerization
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study respectively. The GALLEX system is widely used in many other protein interaction studies,
like hetero-dimerization of alpha and beta subunits of integrins, transmembrane domain
interaction of human ErbB, and the role of transmembrane helix-helix interaction in the assembly
of the major histocompatibility complex.187-189
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3.2 Materials and Methods
3.2.1 Materials
Plasmids pBLM-LexA-wt-GpA, pBLM-LexA-mut-GpA and strains SU101 are gifts from
professor Dirk Schneider from University of Mainz (Germany).

3.2.2 Cloning and expression of LexA-AcrB fusion proteins
The gene encoding AcrB was amplified by PCR from the template plasmid pBAD33-AcrB. The
digested fragment was inserted in frame into the expression vector pBLM between the restriction
sites SacI and BamHI to create plasmid pBLM-LexA-AcrB. Then plasmid pBLM-LexA-AcrB
was used as the template to construct plasmid pBLM-LexA-11aa linker-AcrB following the
published protocol.190 Similarly, plasmids pBLM-LexA-18aa linker-AcrB and pBLM-25aa
linker-AcrB were constructed using the same method. Sequences of the linkers are listed in
Table 3.1.

Table 3.1 Sequences of the linkers between LexA and AcrB.
Linker length

Linker sequence

11aa

ASGSSGGGSGG

18aa

ASGGGGSGGLSSGGGSGG

25aa

GGGSGGGASGGGGSGGLSSGGGSGG

62

3.2.3 Ethidium bromide (EtBr) accumulation assay
To examine if the introduction of LexA DBD at the N-terminus of AcrB affect the structure and
function of AcrB, EtBr efflux activity of BW25113acrB containing plasmid pBLM-lexAlinker-AcrB were tested. The EtBr accumulation assay was performed following a wellestablished protocol.191 Briefly, the bacterial cells containing different AcrB mutants were
cultured to an OD600 of 1. The cells were harvested and resuspended in buffer containing 10 mM
sodium phosphate, 100 mM sodium chloride, 0.1% glycerol, pH 7.4 at a final OD600 of 0.2. Five
μM EtBr was added to the diluted cells to monitor the fluorescence change at the room
temperature using a Perkin Elmer LS-55 fluorescence spectrometer (Perkin Elmer, Waltham,
MA). The excitation and emission wavelengths were set at 520 and 590 nm respectively.

3.2.4 McConkey agar test
Agar plates were prepared by adding 5 g of agar to 100 ml of DI water, following by autoclaving
at 120 oC for 15 min. 15~20 ml hot agar with ampicillin (final concentration 100 mg/L) was
placed in a sterile petri dish. The agar was allowed to cool and harden before SU101 strains
transformed with different plasmids expressing fusion proteins were streaked on the surface of
the agar. Then plates were incubated at 37 oC overnight.192

3.2.5 β-galactosidase activity assay
Activity of β-galactosidase was tested using the Miller Assay.193 Briefly, 20 µl samples of
culture were taken at certain OD600 and mixed into 80 µl permeabilization solution (100 mM
Na2HPO4, 20 mM KCl, 2 mM MgSO4, 0.9 mg/ml hexadecyltrimethylammonium bromide, 0.4
mg/ml sodium deoxycholate, 5.4 µl/ml β-mercaptoethanol). The permeabilization mixture was
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kept for 30 min at 30 oC. Then 600 µl of 30 oC prewarmed substrate solution (60 mM Na2HPO4,
40 mM NaH2PO4, 1 mg/ml o-nitrophenyl-beta-D-galactoside, 2.7 µl/ml beta-mercaptoethanol)
was added to initiate the reaction. After sufficient color developed, 700 µl stop solution (1 M
Na2CO3) was added and the reaction time recorded. All samples were then centrifuged for 10
min at maximum speed. The supernant solution was transferred to a cuvette and the absorbance
at 420 nm was measured. Enzyme activities were expressed by Miller unit, which was calculated
using the following equation:
𝑚𝑖𝑙𝑙𝑒𝑟 𝑢𝑛𝑖𝑡 = 1000 ×

𝐴𝑏𝑠420
𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 × 𝑣𝑜𝑙𝑢𝑚𝑒(0.02𝑚𝑙) × 𝐴𝑏𝑠600
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3.3 Results and Discussion
3.3.1 Design and construction of fusion proteins LexA-AcrB with various linkers
GALLEX has been widely used to detect dimerization of small membrane proteins (intact or
segment). Due to the small size of those membrane proteins, fused LexA DNA binding domains
are easily pulled together and dimerize, and then subsequently bind to promotor of LacZ which
directly suppresses the production of beta-galactosidase. In this project, if LexA is directly linked
to N-terminus of AcrB, it would be difficult for LexA monomers to encounter each other and
dimerize, since AcrB is a large protein. I used the software Pymol to measure the distance
between two AcrB monomers in a trimer, and found that the linear distance between the Nterminus of each AcrB pair is approximately 21 Å (Fig 3.3). The axial distance between two
adjacent residues in alpha-helix is 1.5 Å, and 3.5 Å in beta-sheet. Assuming each residue in the
linker fusing LexA and AcrB contributes 2 Å in length, at least 5 amino acids are needed to
enable LexA dimerization. I constructed a series of fusion proteins with different linker length,
11aa, 18aa and 25aa using fast cloning method.190 The template used is plasmid pBLM-LexAAcrB, which is prepared by inserting AcrB into vector pBLM-LexA between digestion sites SacI
and BamHI. There are five amino acids between LexA and AcrB, which is ASGSS due to the
sequence of the digestion site. To make the 11aa linker, one unit of GGGSGG is added after
ASGSS. For 18aa linker construct, two units of GGGSGG were added. For 25aa linker construct,
there are three units of GGGSGG.
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Figure 3.3 Linear distances between the N-terminus of neighboring AcrB monomers. Distance is
measured by software Pymol. (created from 2GIF.pdb)162

3.3.2 Fusion of LexA DNA binding domain with various linkers to AcrB didn’t affect the
activity of the AcrAB-TolC system
Ethidium bromide (EtBr) is weakly fluorescent in aqueous buffer, but its fluorescence greatly
increases upon intercalating into DNA.194 As a substrate of AcrB, the entrance of EtBr into E.
coli can be monitored through an increase of fluorescence emission, which gradually reaches a
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plateau at saturation. In the presence of AcrAB-TolC, EtBr accumulates inside the cell very
slowly and fluorescence intensity barely increases. Without the active efflux by AcrAB-TolC, it
can enter the cell at a much faster rate, which results in a rapid elevation of fluorescence
emission. To test the activity of fusion proteins LexA-AcrB with various linkers, EtBr
accumulation assay was performed using intact BW25113 or BW25113acrB cells transformed
with plasmids encoding LexA-linker-AcrB constructs. From Figure 3.4, it can been seen that for
all the linker constructs, the fluorescence intensity barely increase, which means that the fusion
proteins LexA-linker-AcrB can be inserted into membrane and actively pump EtBr out of cells .

Figure 3.4 Real-time measurement of ethidium bromide accumulation for BW25113acrB
containing plasmids encoding different LexA-linker-AcrB constructs.
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3.3.3 18aa is the proper linker length, which enables LexA dimerization
McConkey agar is a type of bacteria growth media which is used to differentiate strains by their
ability to ferment lactose. One important component of McConkey agar is neutral red, which is a
pH indicator. When pH of the medium is below 6.8, neutral red turns red. While the pH rises to
above 8.0, the color changes to yellow. The product of lactose fermentation is acidic, which
makes the medium around the colony red or pink. SU101 strains expressing different AcrB
fusion proteins were streaked on McConkey agar plate and incubated at 37 oC overnight. It can
be seen that medium around the strain expressing LexA-18aa-wt-AcrB is pale or yellow, while
the medium around the strains expressing LexA-18aa-R780A-AcrB is red or pink as shown by
Figure 3.5.

Figure 3.5 McConkey agar test result. When IPTG concentration is 1 µM, 5 µM, 10 µM,
medium around strains expressing LexA-18aa-R780A-AcrB is red or pink, while strains
expressing LexA-18aa-wt-AcrB is pale or yellow.

R780A is an AcrB mutant that has compromised trimer stability.195 It was found by our previous
group member Linliang that R780 is a key residue in AcrB, which greatly influences AcrB trimer
association. This residue is located at the trimer interface (Fig 3.6A). When R780 was mutated to
alanine, there is a significant decrease of trimer stability (Fig 3.6B).
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A.

B.

Figure 3.6 AcrB mutant R780A. A. AcrB structure with side chains of R780 and P223 shown in
red. The side chain of R780 is within H bond distance with the carbonyl oxygen of P223 (created
from 2GIF.pdb). B. Blue native polyacrylamide gel electrophoresis for wild-type AcrB (lane 2)
and mutant R780A-AcrB (lane 3, from left). From top to bottom, molecular weights of bands in
lane 1 are marked on the left. Position of AcrB monomer (M) and trimer (T) are marked on the
left. Note: Figure 3.6B was obtained by Linliang and is included here for the completeness of the
discussion

For strains expressing fusion proteins with other linkers, like LexA-11aa-AcrB and LexA-25aaAcrB, there is no difference between the wild-type AcrB and R780A mutant. This result
indicates that the 18aa linker should have proper length to enable LexA DNA binding domains
dimerization and then binding to the target LacZ promotor. It’s possible that 11aa linker is too
short for LexA to form dimers, while 25aa linker might be too long, which reduce the possibility
of dimerization.
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3.3.4 Strain with plasmid expressing LexA-18aa-wt-AcrB is non-lactose fermenting, while
strain with plasmid expressing LexA-18aa-R780A-AcrB is lactose fermenting
The McConkey agar medium around colony containing plasmid pBLM-LexA-18aa-wt-AcrB is
pale, while that of pBLM-LexA-18aa-R780A-AcrB is red or pink. The observation is consistent
with our previous knowledge that wild-type AcrB exists as well-associated trimer, but R780AAcrB cannot form a stable trimer.

3.3.5 SU101 strain with plasmid expressing LexA-18aa-wt-AcrB has lower β-galactosidase
activity than that containing R780A mutant
The function of β-galactosidase in the cell is to hydrolyze lactose to glucose and galactose which
can be utilized as carbon source by bacteria (Fig 3.7A). Besides the natural substrate lactose,
synthetic compounds which have similar structures to lactose can also be cleaved by βgalactosidase. One example of lactose analogue is called o-nitrophenyl-β-D-galactoside (ONPG).
Hydrolysis of ONPG yields one molecule of galactose and one molecule of o-nitrophenol (ONP),
which has a yellow color (Fig 3.7B). When ONPG is in excess in the lydrolysis reaction, amount
of produced o-nitrophenol is proportional to β-galactosidase activity. In E. coli strain SU101, the
lacZ gene is under the control of the wild-type LexA DNA binding domain recognition sequence.
When LexA DNA binding domains dimerize and bind to the promoter of the lacZ gene,
production of β-galactosidase is suppressed. In the presence of ONPG, less yellow color is
produced.
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A.

B.
Figure 3.7 A. Hydrolysis of lactose by β-galactosidase. The products are galactose and glucose.
B. Hydrolysis of o-nitrophenyl-β-D-galactoside by β-galactosidase. The products are galactose
and o-nitrophenol.

In order to maximize the difference between wt-AcrB and R780A-AcrB, two factors during cell
culture were optimized. One of them is culture time after induction. AcrB is a large protein and it
takes time for the cell to accumulate the fusion protein to a certain amount after induction. After
the addition of 3 µM isopropyl β-D-1-thiogalactopyranoside (IPTG), the same volume of culture
was taken out at different time point. And then Miller Assay was applied to measure the activity
of β-galactosidase. As show in Figure 3.8A, the activity difference between wt-AcrB and
R780A-AcrB was small for the first 3 h after induction. After about 6 h of induction, it can be
obviously seen that activity of β-galactosidase for LexA-wt-AcrB was much lower than that of
the mutant, indicating that the activity is suppressed due to LexA dimerization which is caused
by oligomerization of wt-AcrB. At the same time, the mutant strain has higher activity of β-
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galactosidase. This is because LexA domains have less chance to dimerize, when R780A-AcrB
cannot form well-associated oligomer.

Another factor I optimized is concentration of IPTG. Different concentrations of IPTG were used
to induce expression of fusion proteins, 0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM, 500 µM
and 1mM. As shown in Figure 3.8B, low concentrations of IPTG are needed to differentiate wtAcrB and mutant. When IPTG is in the range of 0.5 µM~5 µM, there are bigger activity
difference between the wild-type and mutant. When IPTG concentration is higher than 10 µM,
enzyme activity for both strains are lower, and the difference between them become less obvious.
This might be due to higher concentration of IPTG makes cell less healthy, which results in
lower enzyme activity for both strains.
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A.

B.
Figure 3.8 Miller Assay result for strains SU101 expressing LexA-wt-AcrB (red) or LexAR780A-AcrB (blue). Role of culture time when IPTG concentration is 3 µM (A) and IPTG
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concentration when culture time is 5h (B) were studied. (Range of IPTG concentration: 0.1 µM,
0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM, 500 µM, 1 mM)
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3.4 Conclusions
GALLEX is a system that can be used to measure the oligomerization capacity of simple
transmembrane helix. In this project, I modified the system to differentiate oligomerization status
between wt-AcrB and mutant AcrB. By constructing a series of fusion proteins with different
length linkers between LexA and AcrB, I found that when there is an 18aa linker fusing LexA
and AcrB, oligomerization difference between the wild-type and mutant can be displayed by
testing the activity of β-galactosidase. After culture condition optimization, it was found that wt
strain has 25% lower enzyme activity compared with the mutant strain, when induced for 6 h by
1 µM IPTG. In published research, which applied GALLEX system to study oligomerization of
GpA TM single helix, there is about 50% difference of enzyme activity between the wild-type
and mutant.52 In this study, GpA TM helix is very small, containing only 19 amino acids. For my
project, AcrB is a big membrane protein which has 1049 residues for each monomer. I think the
giant size of AcrB is the primary reason why the enzyme activity difference can only reach to
25%. Another possible reason for the smaller difference might be that AcrB is a trimer, while
only dimer of LexA is needed to bind to promoter. Maybe trimerization of AcrB makes
dimerization of LexA less efficient.
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Chapter IV Life time measurement of a constitutively expressed multidrug efflux pump

4.1 Introduction
Proteins are a major component of all cells and play many essential roles as structural materials,
building blocks, catalytic elements, transporters, channels, and signaling molecules. Life times of
specific proteins are closely correlated with their stability, function, and the metabolic status of
the cell. Half-lives of proteins in cells range from minutes to days and is usually monitored
using pulse-chase experiments involving isotope labeling, in which cells are exposed to a
specific isotope (H3, C14, or S35-Met) for a short period of time (pulse) before switched into a
normal culture medium (chase).196-199 The degradation of the isotopically labeled protein is then
monitored over time. While the pulse-chase experiment has the advantage of being highly
sensitive, convenient, and generally applicable to all proteins, the involvement of radioactive
materials makes it a potential health hazard and undesirable for experiments that last for several
days. A non-radioactive method, which replaced radio isotopic labeling with a non-natural amino
acid azidohomoalanine (AHA) (Figure 4.1), has been developed and applied in many different
researches.200-201 Orphan lab has developed this approach to visualize newly synthesized proteins
in environmental microbes in situ.202 Schuman et al. have used this method to measure the lifetime of TrkB, a neurotrophin receptor, and the presynaptic protein Bassoon.203 Due to their
structural similarity, AHA can be incorporated into protein sequences by methionyl-tRNA
synthetase if methionine (Met) is not available. Subsequently, the AHA-containing protein can
be detected after purification/immune-precipitation and labeling with probe molecules containing
an alkyne group via the well-established click chemistry.204 In this study, the half-life of
multidrug efflux pump protein AcrB in E. coli was determined, using both the conventional S35Met pulse-chase method and the non-radioactive AHA-labeling method. I found that the
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lifetimes of AcrA and AcrB are extraordinarily long (six days), many times of the doubling time
of E. coli cells.

Figure 4.1 Structures of methionine and AHA.
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4.2 Materials and Methods
4.2.1 Materials
Strain DL41 was obtained from the Coli Genetic Stock Center (Yale University). The custom
polyclonal rabbit anti-AcrA antibody was obtained from GenScript (Piscataway, NJ).

4.2.2 Creation of gene knockout strains
Knockout strains DL41ΔacrB and DL41ΔacrAB were created using Quick & easy E. coli gene
deletion kit (Gene Bridges GmbH, Heidelberg, Germany) following the manufacturer’s protocol.
The target genes in the knockout strains were replaced with a kanamycin resistance cassette.
Colony PCR was applied to confirm that target genes have been replaced.

4.2.3 EtBr accumulation assay
The EtBr accumulation assay was performed as described in section 3.3.3.
4.2.4 Pulse chase experiment
E. coli cells containing respective plasmids were cultivated overnight at 37 °C in LB broth and
diluted 50-fold into 6 mL LB broth on next day. When the OD reached 1.2, cells were harvested
at 4,500 rpm for 10 min at room temperature, resuspended in 6 mL M9 medium, and then
cultured at 37 oC with shaking overnight. Next morning cells were harvested and resuspended in
6 mL M9 medium with 19 amino acids (no methionine). S35-Met (1000 Ci/mmol) was added to
final concentration 50 μCi/ml for 2 min, and then a 400-fold excess of non-radioactive Met (20
mM) was added. The cell culture was returned to the shaker, and aliquots of samples (1ml for
each sample) were withdrawn at the indicated time, centrifuged and frozen. After all samples
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were obtained, cells were resuspended in 200 µl buffer containing 20 mM sodium phosphate (pH
7.5), 0.2 M NaCl, 10% glycerol, 1 mM PMSF, and 0.4% lysozyme. Cells were lysed via
freezing/thawing (F/T) cycles: cell suspension samples were incubated in ethanol/dry ice bath (72oC) for 3 min, then transferred to room temperature water bath for 5 min (20 oC). Between
each F/T cycle, samples were vortexed for 1 min. The freezing/thawing/vortexing process was
repeated for 6 times to make sure cells were lysed. The membrane fraction was collected by
ultra-centrifugation (100,000×g, 1 hour) and then suspended in phosphate buffer containing 1%
(w/v) DDM. Insoluble material was removed by centrifugation. The extracted protein in
supernatant was purified using NTA superflow resin as previously described.205 Protein was
analyzed by SDS-PAGE, and radioisotope-labeled protein was visualized by Typhoon FLA 9500
laser scanner.

4.2.5 AHA incorporation and labeling
Plasmids pQE70-AcrB and pQE70-AcrB-Dloop were constructed in a previous study.205 They
were transformed into DL41ΔacrB or DL41ΔacrAB for protein expression under the basal
condition without induction. E. coli were cultured overnight at 37 °C in LB broth. On the next
day, overnight culture was diluted 250-fold into the M9 minimum medium, and cultured at 37 oC
overnight. On the third day, the overnight culture was diluted 10-fold into fresh M9 medium
containing 19 amino acids (40 μg/ml) and AHA (50 μg/ml). After the indicated incubation time,
cells were harvested by centrifugation and either used directly for protein purification or frozen
as indicated.
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AcrB extraction and purification were conducted as described using NTA superflow resin except
for the following modifications.205 The cells were resuspended and lysed in 20 mM sodium
phosphate (pH 7.5), 0.2 M NaCl, 0.03% DDM, and 1 mM PMSF, washed using the same buffer,
and eluted using 10 mM sodium acetate, 100 mM NaCl, 3% SDS (pH 4.0). After elution, the pH
of the fraction was adjusted back to pH 7.4 using an aliquot of 1 M phosphate buffer for the
labeling reaction.

In AcrA lifetime experiment, cells were collected from 5 mL of culture and resuspended in a
buffer containing 20 mM sodium phosphate (pH 7.5), 0.2 M NaCl, 10% glycerol, and 1 mM
PMSF. After the cells were disrupted using sonication, the membrane fraction was collected by
centrifugation and then solubilized in sodium phosphate buffer containing 1% Triton X-100 for 2
h. Protein extraction solution was incubated with anti-AcrA antibody (5 μl) at 4 °C in a rotator
for 2 h. PMSF and protease inhibitor cocktail was added to inhibit protein degradation. Protein A
beads were washed with sodium phosphate buffer and incubated with 5% BSA in sodium
phosphate buffer in 4 °C for 2~4 h to decrease non-specific binding. After incubating the protein
extraction solution with BSA saturated protein A beads at 4 °C for 1 h, beads were washed with
0.1% Tween-20 in sodium phosphate buffer for 4 times. Protein AcrA was eluted with 3% SDS
sodium phosphate buffer (pH7.5) by incubation for 10 min at 70 °C.

The click reaction was performed following a published protocol.206 Purified AHA-containing
protein was incubated with 200 μM Tris(benzyltriazolylmethyl) amine (TBTA), 500 μM
ascorbic acid, 50 μM alkyne-biotin (PEG4 carboxamide-Propargyl Biotin), and 200 μM CuSO4.
The reaction was allowed to proceed overnight at room temperature and analyzed using antibiotin Western blot.
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4.3 Results and Discussion
4.3.1 The incorporation of AHA did not affect the activity of the AcrAB-TolC efflux system
While the incorporation of AHA into the sequence of proteins has been demonstrated in several
cases, it is not always clear if the replacement of Met by AHA would affect the structure and
function of the protein to be studied. We used a well-established EtBr efflux assay to investigate
if the replacement of Met by AHA would affect the structure and function of the AcrAB-TolC
system.191 EtBr is actively transported by the AcrAB-TolC system. In the absence of AcrB, EtBr
diffuses across the cell membrane into the bacteria, upon which its fluorescence increases
drastically due to intercalation into nucleic acid. In the presence of active pumping, the outward
efflux counter-acts the effect of the inward diffusion and EtBr is effectively removed from the
cell. Therefore, the fluorescence does not increase as significantly.

We first created an acrB gene knockout strain of DL41 (DL41ΔacrB), and then transformed a
plasmid encoding AcrB into the strain (DL41ΔacrB-pQE70-AcrB). As shown in Figure 4.1,
DL41ΔacrB rapidly accumulated EtBr, while the wild-type DL41 did not. The introduction of
pQE70-AcrB reduced the EtBr fluorescence of DL41ΔacrB to a level close to that of the parent
strain, indicating that AcrB encoded in the plasmid is fully functional. Next, we used the acrB
knockout strain to examine the effect of AHA incorporation on AcrB activity. In addition, since
the incorporation of AHA is not protein-specific, it is necessary to confirm that the replacement
of Met by AHA in general does not affect the growth and EtBr accumulation of the bacteria.
DL41ΔacrB transformed with pQE70-AcrB were cultured in a minimum media supplemented
with 19 essential amino acids plus Met or AHA, and their EtBr accumulation plots were
collected (Figure 4.2). The fluorescence of DL41ΔacrB-pQE70-AcrB remained low in both Met81

and AHA-containing media, indicating that the activity of the efflux system was not affected by
replacing Met in the proteins with AHA.

Figure 4.2 Real-time measurement of EtBr accumulation for strain DL41, DL41 ΔacrB and
DL41ΔacrB-pQE-AcrB in different medium (green is LB medium, purple is AHA-containing
medium, blue is Met-containing medium). Note: the green curve is overlapped with the purple
one.

4.3.2 The life-time of AcrB is longer than 24 hours as measured using the S35-Met pulsechase experiment
We first used the conventional S35-Met pulse-chase experiment to estimate the life time of AcrB.
DL41ΔacrB-pQE70-AcrB was used in this study. The bacteria were cultured in the presence of
50 uCi/ml (1000 Ci/mmol) S35-Met for 2 min, and then a 400-fold excess of non-radioactive
Met (20 mM) was added. The cell culture was returned to the shaker, and aliquots of samples
were withdrawn at the indicated time and analyzed (Figure 4.3). The intensity of the
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radioactively labeled AcrB did not decrease over 24 hours. To confirm that the observation was
not due to signal saturation or other artifacts, we repeated the experiment multiple times and
tested the samples with different dilutions. The same conclusion was reached at each time. The
need for performing experiments with long incubation time lasting for several days prompted us
to look into an alternative method that does not require the usage of radioactive compound.

Figure 4.3 Degradation of S35-Met-AcrB determined by pulse-chase experiment.

4.3.3 Determination of the half-life of AcrB through the incorporation of AHA
The incorporation and labeling of AHA was developed as a non-radioactive method to trace
proteins.207 Its application has been demonstrated for several soluble proteins. To make the
method useful for integral membrane proteins, we conducted extensive experiment to optimize
the condition.

4.3.3.1 Optimization of labeling condition
To make AHA-containing proteins visible for detection, a labeling step has to be performed in
which the click chemistry is used to attach a probe (a fluorescent dye or biotin) to the azido
group in the side chain of AHA. A major challenge of applying the AHA-based tracing method
to integral membrane proteins is the difficulty of reacting AHA with the alkyne probe. Our initial
attempts of following the literature protocol for soluble proteins yielded very low level of
labeling. In membrane proteins such as AcrB, the AHA side chains (originally Met side chains)
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tend to be less accessible for reaction as compared to their counterparts in soluble proteins. We
found that the following modifications are essential for the application of the method to AcrB.

First, the most important factor affecting the outcome of labeling is the unfolding of the target
protein. We found that the protein needed to be fully unfolded to yield reproducible and high
level of labeling. We experimented with unfolding AcrB using 8 M urea and 3% SDS before
proceeding to the click reaction. Without the presence of denaturing reagent, no labeling could
be observed. When 8 M urea was present, a weak labeling signal could be observed, indicating a
small percentage of AHA became accessible to reaction. Decent labeling could only be achieved
after the protein was completely unfolded using 3% (w/v) SDS before labeling.

Second, another important factor for reaction is the reducing reagent. In the click chemistry
reaction the Cu (I) catalyst is prepared in situ by reducing a Cu (II) salt with a reducing agent.
While many studies in literature reported using tris (2-carboxyethyl) phosphine (TECP) as the
reducing reagent, we found ascorbic acid worked better in our experiment.208

In addition, we found that imidazole had an inhibitory effect on the click reaction. Our AcrB
constructs contain histag at their N-termini for purification.

When high concentration of

imidazole was used for elution, the fractions could not be used directly in labeling. The presence
of imidazole, even as low as 1 mM, significantly inhibited the labeling reaction. After imidazole
was removed via dialysis, the reaction could occur. To simplify the labeling procedure, we
eluted our protein using a change of pH as described in Materials and Method. The elution buffer
was 10 mM sodium acetate (pH 4.0), 100 mM NaCl, 0.03% DDM. The reduction of pH leads to
protonation of the histidine side chains in the histag, which effectively disrupted the interaction
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with the Ni-NTA resin. Because labeling will be conducted under denaturing conditions, the
potential effect of low pH on protein folding is not a concern for this application. After elution,
the pH of the fraction was adjusted back to pH 7.5 using an aliquot of high concentration
phosphate buffer for the labeling reaction.

4.3.3.2 The dilution effect
Due to the long life-time of AcrB, an unavoidable technical concern emerged: the dilution effect.
When a parent bacterium divides into two daughter bacteria, the AHA-labeled proteins are also
divided into the two daughter cells. As shown in Figure 4.4, the starting E. coli cell (1st
generation) is cultured in a media containing AHA but not Met. Assuming the cell has 8
molecules of AcrB, all containing AHA (Blue). The cell is then transferred into a media
containing Met (but not AHA). After the cell doubles, the two daughter cells (2nd generation)
each still contains 8 molecules of AcrB, but only 4 molecules in each cell contains AHA. The
other 4 molecules, which are newly synthesized in the absence of AHA, are not labeled.
Accordingly, four and eight E. coli cells are produced in 3rd and 4th generations, respectively,
with 25% or 12.5% of their AcrB molecules containing AHA. Therefore, to trace the
disappearance of AHA-labeled AcrB, care has to be taken to collect all offspring from the same
number of cells at each time point.
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Figure 4.4 The dilution effect. Assume the starting E. coli cells (1st generation), which are
cultured in AHA-media, contains 8 molecules of AHA-AcrB (Blue). After the cell is transferred
into a media containing Met (but not AHA), the 2nd generation cells each still contains 8
molecules of AcrB, but only 4 of them contains AHA (blue). The other 4 newly synthesized
AcrB molecules contain normal Met (yellow). Accordingly, the 3rd and 4th generation cells
contains 25% or 12.5% AHA-AcrB (blue), respectively. Potential effect of degradation is not
considered in this scheme.

Therefore, for this study, the proper sampling approach is to divide the AHA-containing E. coli
cells into n+1 parts (for sampling of n days) (Figure 4.5). On day 0 (right before switching into a
Met-media), one part is centrifuged to collect the cells and frozen. The rest of the samples are
cultured to allow the E. coli cells to grow and divide. After one day, the second sample is
centrifuged to collect the cells, and frozen. And so on until the nth day. To keep the cells viable,
all cultures were centrifuged each day and resuspended into fresh media. The number of cells
kept on increasing each day until they reach saturation, so did the amount of AcrB purified from
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the cell pellet. But since the amount of starting materials, the AHA-containing AcrB, was the
same in each sample, the observed decrease of the intensity of the biotinylated AHA-AcrB band
reflected the degradation of AcrB molecules produced during the incubation time in which AHA
was present in the media.

Figure 4.5 Sampling method used to detect lifetime of AcrB.

4.3.3.3 Determination of the lifetime of AcrB
To determine the lifetime of AcrB, we first cultured E. coli cells in the presence of AHA, and
then chased using Met for seven days. To make the experiment practical, we kept the overall
volume of the culture fixed at 10 mL. We acknowledge keeping the OD, or cell density, fixed
over time would be a more desirable approach. However, we found that we cannot slow down
the growth enough to keep the culture volume practical over the seven days experiment period.
Another concern about the increase of volume is the drastic difference of cell mass, which would
make it impossible to scale the purification and labeling protocols in a proper way to compare
samples collected in successive days.

The analyses of AcrB samples extracted from cell pellets collected over seven days were shown
in Figure 4.6. Figure 4.6A is the coomassie blue stain to reflect the overall level of AcrB, while
Figure 4.6B is an image of the anti-biotin Western blot of the same set of samples. The band
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intensities of the coomassie stained gel increased over time, as a result of an increase of the
overall number of cells. Due to the limitation of volume, the overall number of E. coli, and thus
the AcrB extracted from the sample, did not increase further once the cell culture reached
saturation. The biotinylated AHA-AcrB band is clearly visible for the first 5 days of incubation,
and becomes much smaller in day 6. Figure 4.6C shows the degradation process of S35-MetAcrB by using pulse-chase method over longer chase time, which is 7 days. From the image, it
can be seen that the bands intensity decrease gradually. On day 7, the radioactive signal can
barely be detected, which is consistent with the result from AHA-incorporation method. We
conclude that the life-time of AcrB in E. coli cells under our experimental condition was 5-6
days.

Figure 4.6 Tracing the disappearance of AcrB by using both AHA-incorporation method and
S35-Met pulse-chase method. A. Commassie blue stain of purified AcrB from samples collected
after the indicated time. B. Anti-biotin western blot of purified AcrB from samples collected
after the indicated time. C. Degradation of [35S]-Met-AcrB determined by pulse-chase
experiment. Note: Figure 4.5C was obtained by our group member Zhaoshuai and is included
here for the completeness of the discussion.
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4.3.3.4 Lifetime of a functionless AcrB mutant
AcrB is constitutively expressed. The level of AcrB in E. coli does not response drastically with
the concentration of potential inducers in the environment. For example, Rosenberg et al. have
shown that the presence of various cholates induced the production of AcrB by 1.1 to 1.7
folds.209 Therefore, we speculate that the long lifetime of AcrB is not correlated with its function,
since the production of the protein is not sensitive to the presence of substrate in the environment
(and thus the need for active efflux). To examine if this is the case, we determined the lifetime of
a functionless mutant, AcrB-Dloop.205 In this mutant, residues 211 to 227, which are important
for inter-subunit interaction, were deleted. We monitored the degradation of AHA-labeled AcrBDloop as described above, and found that it lasted for 4-5 days before the AHA signal
disappeared (Figure 4.7). Compared with the lifetime result of the wild-type AcrB, functionless
AcrB-Dloop doesn’t have a significantly shorter lifetime, which indicates that active efflux is not
a prerequisite for the long lifetime of the protein.

Figure 4.7 Tracing the disappearance of AHA-containing AcrB-Dloop via biotinylation. A.
commassie blue stain. B. anti-biotin Western blot.
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4.3.3.5 Effect of AcrA on AcrB stability
AcrA is a periplasmic protein partner of AcrB. Both proteins, as well as the outer membrane
channel TolC, are critical for drug efflux. While it is generally accepted that TolC does not
constantly forming a docking complex with AcrA and AcrB, it was less clear if AcrA and AcrB
interact with each other in the absence of active efflux. If the presence of AcrA influences the
lifetime of AcrB, then they are more likely to form a complex even without active efflux. To
examine the effect of AcrA on AcrB lifetime, we created an acrA and acrB double knockout
strain, DL41ΔacrAB, and then compared the lifetime of AcrB (Figure 4.8). We found that the
absence of AcrA significantly reduced the lifetime of AcrB by 2 days. The AHA-AcrB signal
disappeared after 3 days. This observation suggests that AcrA interacts with AcrB even in the
absence of active efflux. And such interaction helps to stabilize the structure of AcrB in the cell
membrane and increase its lifetime.

Figure 4.8 Tracing the disappearance of AHA-containing AcrB via biotinylation in the absence
of AcrA. A. Commassie blue stain. B. Anti-biotin Western blot.

4.3.3.6 Lifetime of AcrA
The gene expressing AcrA and AcrB are clustered, with the starting codon of acrB only 23 bases
downstream of the stop codon of acrA. Therefore, they are likely to share the same mRNA
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during protein production. Since the functions of AcrA and AcrB depend closely on each other,
we speculate that the lifetime of AcrA is likely to be comparable to that of AcrB. Using the same
method, we determined the lifetime of AcrA. We found that AHA-AcrA also lasted for 5-6 days
in E. coli cells under the same experimental condition, consistent with our expectation (Figure
4.9).

Figure 4.9 Tracing the disappearance of AHA-containing AcrA via biotinylation. A. Commassie
blue stain. B. Anti-biotin Western blot.
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4.4 Conclusions
In summary, we found that the life time of AcrA and AcrB were several days in E. coli cells. We
have to point out that the metabolic condition of the cells must have an impact on the life time of
proteins in the cells. In our experiment, we had to fix the volume of the culture to make it
experimentally practical to compare samples collected over seven days. Therefore, for samples
of later dates the cell density in the culture was constantly in the state of saturation, and we
changed the cells into fresh media every day to keep the cells viable. Despite of this limitation,
we were able to obtain interesting information about the lifetime of an important efflux
transporter in E. coli. We found that the longevity of AcrB does not correlate with active efflux,
but depend on the presence of its protein partner AcrA. The lifetime of AcrA is comparable to
that of AcrB, which is reasonable as AcrA and AcrB are likely co-translated and their cellular
functions are correlated.

The average lifetimes of proteins in different organisms have been the focus of several studies.
Belle et al. measured the half-life of 3,751 proteins in the yeast proteome and found the
distribution of half-lives to be approximately log-normal, with a mean and median half-life of
~43 min.210 Systematic studies of mammalian cell lines cultured in vitro reveal that the average
half-life of proteins ranges from hours to days, while the degradation rates of different protein
families seemed to be conserved between mouse and human.211, 212 Similar studies on E. coli
were performed several decades ago. The half-life for bacterial proteins has been reported to be
~20 h.213-216 In a more recent study, Larrabee et al. monitored the turnover of ~250 soluble
proteins in E. coli growing at the log phase and found that the majority of them were not
degraded to any appreciable extent in 70 min.198 These studies indicate that although the
doubling time and protein synthesis rate of bacteria cells are many folds faster than that of the
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eukaryotic cells, the protein degradation rate in general is not significantly faster. Different
proteins in the same cell could have drastically different rate of degradation. AcrA and AcrB are
undoubtedly among the longer lived ones. This is consistent with their preventative protection
role in the cell. It is intriguing to ask if membrane proteins tend to have longer life time
compared to soluble proteins. On the one hand, the biogenesis of membrane proteins consumes
more energy as the nascent polypeptide chain needs to be targeted and inserted into the proper
membrane. On the other hand, the degradation of membrane proteins required the removal of the
highly hydrophobic transmembrane segments from the membrane. The answer to this question
requires the analysis of the lifetime of more membrane proteins, which had been hindered by the
intrinsic difficulty to extract and characterize these highly hydrophobic targets.
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Chapter V The ssra-tag facilitated digestion of an integral membrane protein

5.1 Introduction
In bacteria, the major players in protein degradation are ATP-dependent proteases, including
HslUV, ClpAP, ClpXP, Lon, FtsH, and their homologs.217-220 These proteases utilize their
ATPase functions to facilitate the unfolding and translocation of substrate proteins. Among them,
ClpAP and ClpXP are complexes of two proteins, an unfoldase ClpX/ClpA, and a peptidase
ClpP.221-223 By itself ClpP can degrade small peptide substrates, but to degrade larger proteins it
needs to form a complex with an ATPase, such as ClpA or ClpX, which dissociates stable
protein complexes and unfolds proteins at the expense of ATP hydrolysis (Figure 5.1A). One
role of the ClpXP and ClpAP complexes is to degrade proteins bearing the ssrA-tag. In bacteria,
the ssrA-tagging system is evolved to get rid of incompletely synthesized proteins which result
from stalled synthesis of the ribosome.224-226 They are tagged for destruction by the cotranslational addition of an 11-residue peptide (AANDENYALAA) by an amazing molecule tmRNA (Figure 5.1B).227,

228

This ssrA mechanism effectively degrades nonsense proteins and

releases/recycles ribosomes.72, 229 While the degradation of ssrA-tagged soluble proteins has
been well studied, similar process of membrane proteins has not been investigated. Here we
report that the introduction of the ssrA-tag lead to the complete degradation of a large integral
membrane protein AcrB.
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A.

B.
Figure 5.1 A. degradation process of ssra-tagged protein by ClpA/X-ClpP system. B. Addition of
ssra-tag to translation stalled protein. Reprinted by permission from Macmillan Publishers Ltd:
[Nature structural and molecular biology] (The SsrA-SmpB system for protein tagging, directed
degradation and ribosome rescue), copyright (2000).
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5.2 Materials and Methods
5.2.1 Creation of gene knockout strains
Strains DL41, BW25113 and its single gene knockout strains were obtained from the Coli
Genetic Stock Center (Yale University).

Gene knockout strains DL41ΔacrBΔclpX,

DL41ΔacrBΔclpA, DL41ΔacrBΔclpP, and DL41ΔacrBΔsspB were created using Quick & Easy
E. coli gene deletion kit (Gene Bridges GmbH, Heidelberg, Germany) following the
manufacturer’s protocol. The target genes in the knockout strains were replaced with a
kanamycin resistance cassette. Colony PCR was used to confirm that target genes had been
replaced.

5.2.2 Construction of plasmids
The gene encoding AcrB was amplified by PCR from E. coli genomic DNA and then digested
with SphI and BamHI. A stop codon was added after the last acrB codon. The fragment was
inserted into an expression vector pQE70 between the restriction sites SphI and BglII to create
plasmid pQE-AcrB. For pQE-AcrB-His6, the stop codon was not included. The acrB gene was
inserted in frame to the vector-derived C-terminal histag. To create pQE-AcrB-ssrA and pQEAcrB-His6-ssrA, pQE-AcrB or pQE-AcrB-His6 was used as the template, respectively. The
oligonucleotide encoding the ssrA-tag was inserted after the last acrB codon using one-step PCR
following the method described in literature.190

Plasmids were also constructed to express ClpP and ClpX with a His6 tag. Plasmid pQE70-His6ClpP was obtained from Addgene. The gene encoding ClpX was inserted into the vector pET28a

96

in frame between the restriction enzyme cutting sites NdeI and XhoI to create pET28a-His6ClpX.

5.2.3 Analysis of AcrB amount by Western blot
The indicated plasmid was transformed into the corresponding strains. To examine AcrB
expression under the basal condition, 3 mL of E. coli cells were cultured overnight and collected
via centrifugation. The cell pellet was sonicated in a lysis buffer (50 mM Na-Pi pH 7.5, 100 mM
NaCl). Next, the SDS-loading dye was directly added into the lysate and the samples were
resolved using SDS-PAGE, followed by Western blot using an anti-AcrB antibody raised against
a peptide sequence corresponding to residues 1032 to 1045 of AcrB (AcrB-CT-antibody) or
against purified full length AcrB (AcrB-FL-antibody).230

5.2.4 S35-Met pulse-chase experiment
The pulse-chase experiment was performed as described in section 4.2.4.

5.2.5 Protein expression and purification
To avoid potential contamination from genomic AcrB, pQE-AcrB-His6 and pQE-AcrB-His6-ssrA
were transformed into DL41ΔacrBΔClpX for expression. A single colony from a freshly
transformed plate was used to inoculate 3 mL LB media supplemented with ampicillin and
kanamycin and cultured overnight. The overnight culture was used to inoculate 600 mL of fresh
LB media supplemented with ampicillin and kanamycin. The culture was incubated with shaking
at 37 °C overnight. Cells were harvested the next morning by centrifuge. Protein was purified
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following the procedure described in section 2.2.2. After elution, the samples were dialyzed
against a dialysis buffer (0.03% DDM, 30 mM Tris, 0.5 M NaCl, pH 7.9) overnight at 4 oC to
remove imidazole.

5.2.6 CD spectroscopy
CD was performed using a JASCO J-810 spectrometer with 1 nm bandwidth. The
instrumentation principle of circular dichroism spectrometer is illustrated in the following
diagram.

Figure 5.2 Instrumentation of circular dichroism spectrometer. (Note: this figure was drawn by
referring

to

instrumentation

principle

at

website

http://chemwiki.ucdavis.edu/Core/Physical_Chemistry/Spectroscopy/Electronic_Spectroscopy/C
ircular_Dichroism)
Circular dichroism is an absorption spectroscopy method which detects the absorption difference
of left and right circularly polarized light by chiral molecules, such as proteins and small organic
molecules. As the instrumentation diagram shows in figure 5.2, light is firstly linearly polarized
after passing through a linear polarizer, and then divided into right and left circular polarized

98

light by photoelastic mudulator. Chiral samples have different absorption of left and right
circular polarized light and this difference can provide secondary structural information for
protein samples. Protein samples were dialyzed overnight into a low salt buffer (10 mM sodiumphosphate, 50 mM NaCl, 0.03% DDM, pH 7.5) before the CD measurement. Blank scans were
collected using the exterior dialysis buffer. For far-UV CD spectra, samples in 1 mm path length
cuvette were scanned in the wavelength range of 260–190 nm. All spectra were corrected for
blanks. Protein concentrations were determined using the Bradford assay.

5.2.7 In vivo digestion test
To detect the degradation of AcrB-His6-ssrA in cell upon the induction of ClpX,
DL41ΔacrBΔclpX (kanamycin (kan) resistance) was co-transformed with two compatible
plasmids:

pQE70-AcrB-His6-ssrA

(ampicillin

(amp)

resistance)

and

pBAD33-ClpX

(chloramphenicol (cam) resistance). The strain was cultured overnight in LB-kan/amp/cam, and
diluted 100-fold into fresh LB-kan/amp/cam media the next morning. The cells were cultured at
30 oC with shaking (250 rpm) until the OD600 reached 0.4, and then collected by centrifugation at
4,500 rpm for 10 min. The cell pellet was resuspended into fresh LB-kan/amp/cam and split into
three portions: one portion was left on ice (the “no additional growth” control). Arabinose (0.1%
w/v) was added into the second portion. The second and third portions were cultured for an
additional 2 hours at 28 oC with shaking (250 rpm). Next, all three samples were centrifuged, and
the cell pellets were treated as described in section 5.2.3 and subjected to anti-AcrB Western blot
analysis to measure the amount of AcrB-ssra.
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5.2.8 In vitro digestion assay
Digestion of detergent solubilized AcrB was performed according to the published protocol.231
Briefly, AcrB-His6-ssrA was expressed and purified from DL41ΔacrBΔclpX. After elution, the
sample was dialyzed to remove the high concentration of imidazole. Expression and purification
of His6-ClpX and His6-ClpP were conducted following published protocols.72 The activity of
purified His6-ClpX, His6-ClpP, and the assay buffer system was confirmed using purified GFPssrA as the substrate. For AcrB-His6-ssrA digestion, AcrB-His6-ssrA, ClpX and ClpP were added
at the specified molar ratio in the assay buffer including the ATP regeneration system (25 mM
HEPES-KOH, pH7.6, 200 mM KCl, 10 mM MgCl2, 10% glycerol, 2 mM DTT, 5 mM ATP, 16
mM creatine phosphate, and 0.032 mg/mL creatine kinase) supplemented with 0.03% DDM. A
control sample was also set up which was identical except that no ATP was present. After
incubated overnight, the level of AcrB-His6-ssrA in the presence of ATP was determined using
anti-AcrB Western blot.

5.3 Results and Discussion
5.3.1 The ssrA tag does not change the secondary structure of AcrB
To demonstrate that the addition of the ssrA tag did not affect the membrane integration and
folding of AcrB, we compared the circular dichroism (CD) spectra of purified AcrB-His6 and
AcrB-His6-ssrA (Figure 5.3). AcrB-His6-ssrA was purified from membrane vesicles, indicating
that the membrane integration was not compromised by the C-terminal tag. This is consistent
with our expectation as the membrane integration of inner membrane proteins is co-translational.
For a large protein such as AcrB, the membrane insertion should be close to complete before the
C-terminal ssrA-tag emerges from the exit tunnel of the ribosome. The CD spectra of detergent100

solubilized AcrB-His6 and AcrB-His6-ssrA superimposed well onto each other, indicating the
presence of the tag did not affect the overall folding of the protein.

Figure 5.3 CD Spectra of AcrB-His6 (black) and AcrB-His6-ssrA (grey).

5.3.2 AcrB-ssra can be digested at a much faster rate than the wild-type AcrB
AcrB can be purified and easily crystallized, suggesting that its structure is intrinsically stable.
However, the introduction of the oligonucleotide encoding the ssrA-tag into the acrB gene right
before its stop codon rendered the protein no longer detectable in the cell lysate. We transformed
plasmid pQE-AcrB or pQE-AcrB-ssrA into BW25113ΔacrB and examined protein expression
under the basal condition. As shown in Figure 5.4, wild-type AcrB expressed well and yielded a
clear band on the blot (lane 1). However, after we added the ssrA tag to the protein, its
expression was completely abolished (lanes 2). Earlier studies show that the last five residues
YALAA of the ssrA tag is the critical factor, which also promotes degradation although at a
lower efficiency.74 To confirm that the degradation was actually caused by the tag, we also
constructed AcrB with the truncated ssrA tag (AcrB-5aa ssrA). As expected, the expression level
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of the protein was much lower than that of the wild-type AcrB, but is still clearly observable
(Figure 5.4, lane 3). For the rest of the study, by AcrB-ssrA we indicate AcrB bearing the 11residue ssrA tag at the C-terminus. Since the AcrB-CT antibody recognizes a specific peptide
sequence close to the C-terminus of the protein, we have also repeated the experiment using an
anti-AcrB antibody raised against the full length AcrB (AcrB-FL antibody).

Figure 5.4 Anti-AcrB Western blot analyses of membrane extracts obtained from DL41-acrB
strain containing plasmids encoded wt-AcrB, AcrB-11aa ssra, AcrB-5aa ssra.

To confirm that the lack of AcrB-ssrA is a result of degradation, not a defect in translation, we
conducted the S35-Met pulse chase experiment (Figure 5.5). A His6 tag was inserted at the Cterminus of AcrB, right before the ssrA tag. DL41ΔacrB transformed with plasmids pQE-AcrBHis6 or pQE-AcrB-His6-ssrA was cultured in the presence of S35-Met for 2 min, and then chased
using a large excess of cold Met. As discussed above, AcrB-His6 was very stable and the
intensity did not significantly decrease over the 24 hours of this experiment. In the case of AcrBHis6-ssrA, a clear band could be seen at time 0, indicating normal expression, but the band
102

intensity of AcrB-His6-ssrA dropped to the background level within ~15 min, indicating fast
degradation.

Figure 5.5 Degradation of S35-Met-AcrB-His6 and S35-Met-AcrB-His6-ssra determined by the
pulse-chase experiment. Note the difference in the unit of the time.

5.3.3 Degradation of AcrB-ssra is mediated by ClpXP/SspB system
To investigate if the degradation is mediated by the ClpAP and/or ClpXP, we obtained single
gene knockout strains lacking each gene from the Yale Coli Genetic Stock Center, and
transformed plasmid encoding AcrB-ssrA to examine the level of degradation (Figure 5.6). We
examined the effect of knocking out five single genes, including clpA, clpX, clpP, sspB, prc.
Among them, ClpA is similar to ClpX and also functions with ClpP.224 SspB is a known
chaperone that enhances the degradation of ssrA-tagged substrate by increasing the binding
affinity and lowering the KM.232-235 Of the 11 residues in the ssrA tag, only the terminal AACOOH is directly involved in ClpX binding. Several residues upper stream in the tag
(AANEDNY) mediate binding to SspB, which aids in the delivery of ssrA-tagged protein to
ClpXP.235 Prc is a periplasmic protease (also known as Tsp) that degrades protein substrates in a
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carboxy-terminal-specific manner and is known to degrade ssrA tagged proteins that are exported
to the periplasm.225
Plasmid pQE-AcrB-ssrA was transformed into the indicated strains, and the cellular AcrB-ssrA
level was determined using anti-AcrB Western blot with the AcrB-CT-antibody. We found that
residual AcrB-ssrA could be detected in three strains: ΔclpX, ΔclpP and ΔsspB (Figure 5.6 A, B).
Among them, ΔclpX contains the highest level of residual AcrB-ssrA. And because the strains
still contain the genomic AcrB, a protein band at a slightly smaller molecular weight could be
observed in all samples (the extra amino acids in the tag slowed down the migration of the
protein in the gel). The presence of these two bands further confirmed that the production (or
more likely, degradation) of the wild-type AcrB was not affected in the knockout strains so the
degradation is ssrA-tag specific. In the parent strain (lanes 6 and 7), the transformation with the
plasmid did not lead to a detectable AcrB-ssrA band. The same was observed in the ΔclpA or
Δprc strains, suggesting that ClpA and Prc are not involved.
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Figure 5.6 Anti-AcrB Western blot analyses of membrane vesicles. A. Single gene knockout
strains of BW25113 missing the indicated gene expressing AcrB-ssrA from a plasmid. Result
was analyzed using 8% SDS-PAGE. The last two lanes are the parent strain with or without the
plasmid, respectively. B. Same as in A, but analyzed on a 6% gel to better separate the genomic
AcrB and AcrB-ssrA.

5.3.4 ClpXP is not the only protease system that degrades AcrB-ssra
To determine the level of degradation, we first created double knockout strains to further
eliminate the genomic acrB gene, and then transformed plasmids pQE-AcrB or pQE-AcrB-ssrA
into each strain for comparison (Figure 5.7). Assuming the transcription and translation was not
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affected by the last a few nucleotides/amino acids making up the ssrA tag, the difference in the
detected protein level should reveal information about the level of degradation. We found that
the degradation level in ΔclpX is approximately 60-70%. In ΔclpP and ΔsspB, the degradation
level reached 80-90%. These results indicate that 1) ClpXP and SspB are involved in the
degradation of AcrB-ssrA; 2) there are likely other proteins involves in the degradation as well.

Figure 5.7 Expression of AcrB or AcrB-ssrA in the indicated double knockout strain.

5.3.5 In vivo digestion of AcrB-ssra
Two plasmids pQE70-AcrB-ssra and pBAD33-ClpX were co-transformed into strain DL41ΔacrB-ΔclpX. The reason to choose pBAD33 as a vector to express ClpX is that pBAD33 is a
tightly controlled plasmid, and the expression of ClpX can be switched on in the presence of Larabinose. The DL41ΔacrBΔclpX strain containing only one plasmid pQE-AcrB-His6-ssrA was
also treated similarly and used as a control. When pBAD-ClpX was co-transformed with pQEAcrB-His6-ssrA, the induction of ClpX expression led to a significant drop of AcrB level, which
was not observed in the control strain lacking pBAD-ClpX. Samples 2 and 3 have similar AcrB
levels. This result indicates that the induced expression of ClpX accelerated the degradation of
AcrB-His6-ssrA, including the portion that was synthesized before the time of the induction.
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Figure 5.8 Anti-AcrB Western blot analysis of whole cell lysate prepared from DL41-ΔacrBΔclpX transformed with pQE-AcrB-His6-ssrA and pBAD-ClpX (pClpX) (top) or pQE-AcrBHis6-ssrA alone (bottom). AcrB-His6-ssrA was expressed at the basal level without induction,
and then the cell culture was divided equally into three samples: arabinose was added into the
first sample to induce the expression of ClpX (lane 1). Sample 1 and sample 2 (lane 2) were
incubated for an additional 2 hours at 28 oC, while sample 3 (lane 3) was left on ice.

5.3.6 In vitro digestion of AcrB-ssra by ClpXP system
The ultimate test of the degradation of AcrB-ssrA by ClpXP is to purify each component and
conduct the degradation assay in a test tube. Since AcrB-ssrA is completely degraded in wildtype E. coli, we expressed and purified it in DL41ΔacrBΔclpX. A His6 tag was inserted between
the last amino acid of AcrB and the ssrA tag to facilitate purification. As described above, the
addition of his-tag did not affect the degradation of the protein. The expression and purification
of AcrB-his6-ssrA were performed as described for AcrB-His6.170, 171 After elution, the sample
was dialyzed to remove the high concentration of imidazole. Plasmids were also constructed to
express ClpP and ClpX with N-terminal His6 tag. Expression and purification of His6-ClpX and
His6-ClpP were conducted following published protocols.72 In our preliminary test, we set up
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two reactions, one contains AcrB-His6-ssrA, ClpX, ClpP at a molar ratio of AcrB-His6-ssrA:
(ClpX)6: (ClpP)14 = 1:15:50 in the assay buffer including the ATP regeneration system
supplemented with 0.03% DDM. The negative control was identical except that no ATP was
present. After incubated overnight at 30 oC, the level of AcrB-His6-ssrA in the presence of ATP
was determined using anti-AcrB Western blot to be approximately 30~40% of the control sample.
The level of degradation could not be improved by the addition of more ClpXP or the increase of
digestion time, indicating that under the current experimental condition the efficiency of the
protease is quite low. To better quantify the rate of digestion, a better in vitro assay is clearly
necessary.

Figure 5.9 Anti-AcrB Western blot analysis of degradation of detergent solubilized AcrB-His6ssrA in vitro. Lanes 1 and 2 contain 0.2 µg AcrB-His6-ssrA, and lanes 3 and 4 contain 0.1 µg
AcrB-His6-ssrA. Lanes 2 and 4 also contains ClpX and ClpP at the molar ratio of AcrB : ClpX6 :
ClpP14=1:15:50.

5.3.7 Length of C-terminus of AcrB affects efficiency of digestion by ClpXP
C-terminus of AcrB (from R1031 to H1049) has uncoiled structure and is not inserted into the
membrane (Figure 5.10). We assume that if ClpXP system can digest AcrB-ssra that has properly
inserted into the membrane, the C-terminus length of AcrB should influence its digestion
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efficiency. If AcrB-ssra is digested while being translated, there should be no difference for the
degradation of all AcrB-ssra with different C-terminal lengths.

Figure 5.10 Amino acid sequence of AcrB C-terminus. Orange rectangle represents inner
membrane of E. coli cell. The blue rectangle means the last transmembrane domain of AcrB,
which starts from I991 and ends at R1031. The last residues in different truncated AcrB-ssra are
labeled in red.

A series of ssra-tagged AcrB with shortened C-terminus length were constructed: 1031, 1035,
1039, 1042, 1043, 1044, 1049-AcrB-ssra. The number indicates the last amino acid before histag
and ssra-tag. An anti-AcrB Western blot showed that expression levels of these truncated
proteins without the ssrA-tag are similar as that of the wild-type AcrB. By adding the ssrA-tag,
more and more AcrB-ssrA can be detected when the C-terminus becomes shorter (Figure 5.11A).
1049-AcrB-ssra is completely degraded, while ~90% of 1031-AcrB-ssra remained. For 1039-
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AcrB-ssra, about 50% of it can be digested (Figure 5.11B). This result suggests that ClpXP-SspB
complex may need to interact with a fragment of a certain length that is exposed to the cytoplasm
to initiate digestion of AcrB-ssra.
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A.

B.
Figure 5.11 A. Expression level of different truncated AcrB [(-)ssra] and corresponding AcrBssra [(+)ssra] analyzed by anti-AcrB Western blot. B. Percentage of truncated AcrB-ssra (10311049) that cannot be digested.
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5.4 Conclusions
In summary, we discovered that the introduction of an extra 11 amino acid residues, the ssrA-tag,
at the C-terminus of this large 1049-residue and highly stable integral membrane protein leads to
its complete degradation.

It was found that ClpX, ClpP, and SspB are involved in the

degradation of ssrA-tagged AcrB in cells. At the same time, there should be other proteases that
participating degradation of AcrB-ssra. In vivo test showed that AcrB-ssra that has been properly
inserted into membrane can be digested by ClpXP. AcrB-ssra with different C-terminus lengths
have various degradation efficiency. This test also confirmed that the well folded and inserted
AcrB-ssra can be digested by ClpXP complex. An in vitro test showed that ClpXP could degrade
detergent-solubilized AcrB-ssrA using purified proteins. The addition of the tag did not have a
detectable effect of the overall secondary structure composition of the protein. These results lead
to an exciting new question: how is an integral membrane protein efficiently degraded by a
soluble protease complex in the cell? The required dislodging of the transmembrane helices of
the protein substrate and even more strikingly, the long hydrophilic loop, through the cell
membrane is extra challenge for the system to concur. Many more studies are clearly required to
elucidate this interesting and fundamentally important question.
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